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Abstract 
Survival time has become an essential outcome of clinical trial, which began to emerge among 
the latter half of the 20th century. A present study was carried out on the survival analysis for 
patients with prostate cancer. The data was obtained from Memorial Sloan Kettering where each 
sample was collected from the recipients of the treatment of radical prostatectomy. The Kaplan-
Meier method was used to obtain and estimate the survival function and median time among the 
primary and metastatic tumor of prostate cancer. Results showed that the metastatic tumor has a 
poor survival rate compared to the primary tumor, which give us a hint that primary tumor has a 
higher probability of surviving. The log-rank test was used to test the differences in the survival 
curves. The results showed that the difference in survival rate between the patients of the two 
groups of tumor was significant with a p-value of 4.44e-15. The second approach was based on 
the efficiency of cox proportional hazards model and parametric model. Some criteria of 
residuals were used for judging the goodness of fit among the candidate models. The cox 
proportional hazard (PH) model provided an effective covariate on the hazard function. As a 
result of cox PH model, the influence of standard clinical prognostic factors is based on the 
hazard rate of prostate cancer patients. These prognostic factors are: prostate specific antigen 
(PSA) level at diagnosis, tumor size, Secondary Gleason grade, and Gleason score which is 
helpful to determine the treatment. The Gleason score [HR 4.835, 95% CI 2.7847- 8.3937, 
p=2.20E-08] has the most significant progression-associated prognosticators and reveal to be an 
effective criteria leading to death in prostate cancer. The Accelerated Failure Time (AFT) was 
applied to the data with four distortions. AFT with Weibull distortions was chosen to be the best 
model for our data by testing the AIC.   
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Chapter1 
Introduction 
This chapter starts with an essential issue in health, which is cancer. Specially, a review of 
prostate cancer with the related prognostic factors is presented. An overview of survival analysis 
is discussed along with important models that are relevant to the present study.   
1.1 Prostate Cancer 
Cancer is a term used for group of diseases where the cells have abnormal behavior of growth 
and division. There are more than 100 different types of cancer. The prostate cancer originates in 
prostate gland in the male reproductive system. Its function is producing fluid that protects and 
nourishes sperm cells in semen. The cancer cell can spread in different ways, such as through 
tissue, lymph system, and blood (National Cancer Institute). Prostate cancer is the second most 
common malignant cancer causing death in men, after lung cancer, and its incidence increases 
with age. Compared to other cancers, men with prostate cancer can live many years, since it 
grows slowly (Prostate Cancer Canada). Fortunately, prostate cancer in early stages of the 
disease, in half of the new cases, is still confined to the prostate. However, there are a significant 
number of cases of aggressive prostate cancers that can be very devastating. The cell of prostate 
cancer can spread to other parts of the body, which is called metastasis, such as the bones and 
lymph nodes.  
The numbers of new cases of prostate cancer diagnosed each year in the US are approximately 
220,000 and 30,000 of them die of the disease. In addition, the number of new cases of prostate 
cancer in 2013 was 238,590, and the number of deaths was 29,720. In 2014, the new cases of 
prostate cancer diagnosed were about 233,000 and about 29,480 of them died (American Cancer 
Society).  
Research has identified the fundamental risk factors of prostate cancer; they are: age, race/ 
ethnicity, and family history. Among these, age has been found to be the most important factor, 
especially in older men over 60. It is found in the research that surgical radical prostatectomy 
(RP) had better results in young men than in older men. Literature has proved that African 
Americans have higher risk of prostate cancer, approximately 60%, than whites (Litwin et al., 
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2000). If close family members, such as parents and grandparents, have had the disease, it is 
more likely that their children would have it (Prostate Cancer Canada). There are other possible 
factors that may increase the risk such as diet, body mass index (BMI), concomitant medical 
conditions, and hormone profiles,  
1.1.1 Tumors 
Primary Tumor 
When the cancer has begun in any organ or tissue, the original tumor site is referred as the 
primary tumor or cancer. 
Metastatic Tumor 
Metastasis is a process that refers to the spread of cancer. This process can be understood as 
cancer cells breaking away from the primary tumor in the body and then entering the bloodstream 
or lymphatic system. A metastatic tumor or a metastasis is a tumor that is made via metastatic 
cancer cells. The cells can spread to the adrenal gland, bones, liver, and lungs. Metastatic cancer 
occurs exclusively in male patients, affecting the prostate. While the cancer can cause severe pain 
in patients, the depletion of testosterone or ingestion of medications, can improve the patient’s 
urinary function and relieve some pain and discomfort. 
Metastatic cancer is considered to be similar to the primary cancer. In many cases of the 
metastatic, if it is found as the first tumor, then the primary can also be found.  However, some 
patients can have the metastatic without the primary tumor (National Cancer Institute). A 
pathologist examines to determine if a cancer is a primary or a metastatic tumor. 
1.1.2 Prognostic Factors in Prostate Cancer 
Clinical prognostic factors can be obtained through physical examination such as blood tests, 
radiological evaluation, and microscopy of biopsy material. The survival and prognosis of 
prostate cancer is affected by several clinical prognostic factors that give information about the 
cancer characteristics before planning a treatment decision. Some of the factors are the Gleason 
grades, PSA test, and size of tumor stage. They determine the survival rate after surgical radical 
prostatectomy. 
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Prostate-specific antigen (PSA) 
The prognosis as well as diagnosis of prostate cancer has been achieved using the PSA (prostate 
specific antigen).  Serum PSA, particularly free PSA is used widely as a marker for monitoring 
the performed surgery and treatment provided specifically for the prostate tissue. The PSA is a 
screen test commonly used for identifying early stages of prostate cancer. Prostate gland has 
cells, which are used for producing a protein called PSA. The human blood has PSA levels that 
are measured using a PSA test. The abnormality or normality of cells is indicated by the PSA 
results. After diagnosis of cancer PSA levels may be used for determining the extent of the 
disease. The levels of PSA that range from 4.0 (ng/ml) or lower were regarded by doctors as 
normal. In contrast, levels of PSA that are above 4 (ng/mL) are an indication that most parts of 
the body are affected by cancer (metastasis). However, from a general perspective, when the 
human body has high levels of PSA, then there is a high possibility that such a person could be 
suffering from prostate cancer. Therefore, it gives us a hint that the PSA test is not perfect. 
Additionally, prostate cancer may be indicated by a gradual increase in the PSA levels. 
The levels of serum PSA are suitable determinants of prognosis outcomes after radiotherapy of 
prostate cancer and tend to increase the prognostic data that is free of tumor stages as well as 
grade (Buhmeida et al., 2006). Once a patient undergoes a radical prostatectomy, doctors will 
typically monitor the PSA levels, looking for any rise in levels which are typical indicators of a 
recurrence of clinical carcinoma (Penn State Hershey Medical Center). Physicians refer to the 
rate of increase as PSA velocity (PSAV). The PSAV is then used to determine the most 
applicable type of treatment along with the treatment’s starting time.  
Although PSA plays an important role in the prediction of long-term survival in patients, the 
follow-up period for monitoring PSA levels needs to be seriously considered (ibid). More 
research that focuses on the length or duration of the follow-up period is necessary before 
researchers can effectively determine the efficiency of this process.  
Gleason grade 
Notably, other factors that pose a high risk revolve around the Gleason score and represent the 
severity involving the prostate cancer tissue; it plays a critical role by helping the doctor in the 
identification of methods that are suitable for treatment of a specific case of cancer. The Gleason 
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technique is used for classifying the scores of cancer cells through analysis of the microscopic 
structure. An important characteristic of Gleason score revolves around its prognostic factor that 
is useful for determining the progression of cancer as well as death. 
In addition, it is the most significant development, which influences the results. Univariate as 
well as multivariate prognosis analyses involving prostate cancer usually considers the Gleason 
grade as a key predictor of patient results (Buhmeida et al., 2006). The Gleason grade is an 
approach that was designed in 1960s by Dr. Donald Gleason (Humphrey, 2004). Two grades, 
which can be used by a pathologist to produce the score when a biopsy sample is being examined 
using a microscope for a specific pattern that ranges between 1-5, whereby 1 represents the 
normal prostate tissue and 5 represents the abnormal prostate tissue. The calculation of the 
Gleason score can be achieved after primary as well as secondary grades have been identified. 
The primary grade indicates the common tumors, which are over 50 percent, whereas the 
secondary grade is a representation of less frequent tumors that produce a score of below 5 
percent. The Gleason score is created by combining the two grades that have a highest score of 
five. It contains a range of 2-10 (Humphrey, 2004). For instance, when the grade of primary 
tumor is three and that of secondary tumor is 4, the sum of the two grades will produce the 
Gleason score, that is 3+4=7 (Russell, et al., 2003). To have a clear understanding of the ways in 
which the Gleason score can indicate same biological behavior, they are classified into various 
groups. The lowest level of cancer is indicated by 6 on the Gleason score (significant 
differentiation of the tumor tissue), whereas 7 represents a mild grade of cancer (moderate 
differentiation of the tumor tissue). Additionally, a level ranging from 8-10 is an indication of 
higher level of cancer (poor differentiation of the tumor tissue). The highest level produces a 
severe cancer that has a rapid rate of separation compared to lower level cancer. 
Tumors Stage 
Notably, prostate cancer staging was achieved using two types of data namely clinical and histo-
pathological data. Clinical information is usually obtained from external cancer symptoms, 
whereas histo-pathological data is obtained after surgically removing and examining the prostate 
tissues. Clinical information plays a critical role in enabling doctors to make decisions regarding 
the treatment. On the other hand, histo-pathological data is widely used for prognosis prediction. 
Because of this, prostate cancer staging considers clinical as well as histo-pathologic data. 
 5  
Doctors particularly examine the size of the tumor (T), the involvement of the lymph node (N), 
visceral presence/metastasis (M) as well as tumor grade (G).  
Additionally, the tumor size is regarded as a possible risk factor of prostate cancer. Studies have 
shown that an increase in tumor size led to an exponential increase in malignant tumors (Chan, 
2012). Indeed, tumor cell has a relation with the risk of mortality amongst prostate cancer 
patients who are on observation (Andreas Josefsson, 2012). After the diagnosis of cancer, tumor 
stage checks the magnitude of severity as well as cancer spread. Table 1.1 describes four stages 
of tumor as T1 – T4, which represent the size as well as the spread of the tumor. 
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Table 1.1: Four stages of Tumor (University of Maryland). 
Stage, T1 - 
T4 
Description 
T1 The tumor cannot be felt or seen using imaging techniques. 
T1a. Cancer cells are incidentally found in 5% or less of tissue samples 
from prostate surgery unrelated to cancer. 
T1b. Cancer cells found in more than 5% of samples. 
T1c. Cancer cells identified by needle biopsy, which is performed because 
of high PSA levels. 
T2 The cancer is confined to the prostate but can be felt as a small well-
defined module. 
T2a. Tumors are in half a lobe. 
T2b. Tumors are in more than half a lobe. 
T2c. Tumors in both lobes. 
T3 The tumor extends through the prostate capsule. 
T3a: the tumor has spread through the capsule on one or both sides 
T3b: the tumor has invaded one or both seminal vesicles 
T4 The tumor is fixed to or invades adjacent structures. 
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1.1.3 Treatment 
Prostate cancer in men may be treated using a variety of techniques such as bisphosphonate 
therapy, chemotherapy, hormone therapy, radiation therapy as well as surgery. The 
aforementioned techniques are utilized separately; however, in certain instances they can be 
integrated. 
The most commonly used technique for treating cancer that has not spread beyond the gland is 
called surgery. A radical prostatectomy (RP) refers to a surgical process, which entails the 
removal of prostate gland alongside the attached seminal vesicles. During this procedure, the 
lymph nodes that are adjacent to the prostrate may be removed simultaneously. Radical 
prostatectomy (RP) is a common alternative for treating prostate cancer that has not spread to 
other areas of the body. Specifically, it is preferred when the patients are younger than 70 years, 
otherwise radiation therapy is preferred (Stangelberger, 2008). The follow up after the RP can 
detect the PSA level, which identifies the patients with elevated risk of local treatment failure or 
metastatic disease. Though PSA level after surgery is high in some cases, patients are still free of 
symptoms for extended periods of time. Therefore, the PSA level may not be enough to initiate 
additional treatment (National Cancer Institute). 
1.2 Survival Analysis 
Since cancer ranks as the second leading cause of death in the world, survival analysis techniques 
have been used to measure the risk, hazards, and average survival time for cancer patients. The 
common research involving cancer is based on time called the survival time. The term ‘survival 
time’ is used in reference to the number of days, weeks and years from the time patient’s 
observance begins until death takes place. Since 1950s, survival analysis has proved to be an 
important technique (Langova, 2008). There are several areas where survival analysis is applied 
which include demography, economics, engineering, epidemiology, health, medicine and 
biology. Additionally, there has been an increase in the use of survival analysis in areas of 
biostatistics as well as pharmaceuticals. There are several objectives for survival analysis which 
include estimation as well as interpretation of survivor function using survival data, comparison 
of survivor functions coupled with assessment of the link involving defined variables and time of 
survival (Langova, 2008). Since the survival analysis was provided with cancer data, we need 
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special data that is called clinical trials. They are conducted to determine the effectiveness of new 
treatment (Singh, and Mukhopadhyay, 2011). Usually in survival studies, the patients are kept 
over a long period of time, so other factors are important to be still continual over the period. 
The dependent variable within the survival analysis is composed of two attributes namely, time-
to-event as well as event status. An endpoint occurs either when the event occurs or when the 
follow-up time has ended. There are several endpoints that can be the events such as death, 
relapse of disease, recurrence of a tumor, recovery or any designated experience of interest as 
shown in Table 1.2. It marks the indicator variable as 1 if the event of interest was observed or 0 
if it was censored.  
Table 1.2: The survival times  
Starting Point End Point 
Surgery Death/ Relapse/ Recurrence.  
Diagnosis Death/ Relapse/ Recurrence. 
Treatment Death/ Relapse/ Recurrence. 
 
Standard statistical methods may not be used widely because the inherent distribution is 
abnormal and there is censoring of data (Bewick, 2004). Censoring of survival time occurs when 
the time of follow-up is available though it might have taken place unnoticed or has not taken 
place. Several techniques utilized in survival analysis include non-parametric, semi-parametric as 
well as parametric. Within the techniques two kinds of information involving clinical trial for 
survival analysis exist namely, censored as well as uncensored data. Exact data (uncensored data) 
refers to a situation whereby the participant is aware until the occurrence of event-of-interest.  
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1.2.1 Censored data 
Censored data emerges as a critical issue for consideration in survival analysis, because it helps 
to indicate the kind of missing information. Censored data arises when a negative event takes 
place for instance, withdrawal of participant, difficulties in tracking the participant, participant 
has not encountered the suitable results or the relevant data is unavailable. Notably, an indicative 
variable with value 1 is used when the uncensored survival time has been identified and value of 
0 is used for right-censored times (Zhao, 2008). Three separate scenarios involving censored data 
that rely on the follow-up times are in existence. However, this relies largely on the stage-level as 
well as risk-level for the patient. 
1. Right censored refers to a patient who may not encounter a time failure for the event-of-
interest until the follow-up duration elapses or withdraws from the study before it ends. 
2. Left censored refers to a situation whereby the event-under-interest takes place prior to 
enrolment. This scenario is not common. 
3. Interval censored this situation takes place when an event-under-interest has a tendency of 
occurring in a specific time (Zhao, 2008). 
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Figure1.1: Illustration of left, right and interval censoring 
 
The crosses in Figure 1.1 indicate when the failure occurs, while the arrows perpendicular to the 
time axis show the actual times (Aaserud, 2011). 
Overall, the feature of censoring implies that special techniques of analyzing are essential. Most 
widely used technique for analyzing is right censored. 
1.2.2 Functions related to survival analysis 
Before choosing a technique for use in survival analysis, it is imperative that two functions, 
which are time dependent, are considered. They include survival function and hazard function 
that may be explained using the survival information. 
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 The survival function S(t) produces the survival probability approximately to time t. The 
survival function is essential for survival analysis. The Kaplan-Meier curve provides the 
survival function.  
𝑆(𝑡) = 𝑃(𝑇 > 𝑡) = 1 − 𝐹(𝑡), 𝑡 ≥ 0.                      (Fox, 2002) 
T represents a positive random variable that covers the time from commencement of the 
observation up to survival. 𝐹(𝑡) is the distribution function.  
 The hazard function h(t) represents the probability condition of death at time t after survival 
time. 
ℎ(𝑡) =  lim
𝑑𝑑→0
𝑃(𝑡 ≤ 𝑇 < 𝑡 + 𝑑𝑡|𝑇 ≥ 𝑡)
𝑑𝑡
 , 𝑡 ≥ 0. 
A relationship between S(t) and h(t) is shown in the formula below: 
ℎ(𝑡) = 𝑓(𝑡)
𝑆(𝑡) =  −𝑑 log 𝑆(𝑡)𝑑𝑡  
𝑓(𝑡) is the density function which gives the fraction of the original group for whom the event 
occurs during the time interval at t adjusted for the width of the time interval. 
If one of 𝑆(𝑡) or ℎ(𝑡) is known, the other can be calculated. 
𝑆(𝑡) = exp �−� ℎ(𝑢)𝑑𝑢𝑑
0
 � = exp�−𝐻(𝑡)� , 𝑡 ≥ 0. 
Where 𝐻(𝑡) is the cumulative hazard function. 𝐻(𝑡) is difficult to interpret, but there is an easier 
way to make a clear interpretation. The way is to think of 𝐻(𝑡) as the cumulative force of 
mortality or if the event were a repeatable process, the number of events expected for each 
individual by time 𝑡.  
The probability density function of T can be defined as 
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𝑓(𝑡) = ℎ(𝑡) exp �−� ℎ(𝑢)𝑑𝑢𝑑
0
 � , 𝑡 ≥ 0. 
Hazard ratio (HR)  
It is expressed as the relative risk that is used to estimate the ratio of the hazard rate. In addition, 
it has been utilized for describing the outcome of the trials therapy in order to figure out the range 
the treatment can shorten the duration of the disease (Singh, and Mukhopadhyay, 2011). 
The processing of statistical data should entail application of relevant techniques. The survival 
module is characterized by four essential techniques to fit survival models. These models are 
illustrated in Table 1.2. The last strategy in Table 1.2 that is more direct is the parametric 
technique (accelerated failure time), whereby there is assumption on the specified functional form 
of the baseline hazard (𝑡). Within this technique several distributions which acquire a central 
point are in existence such as Weibull, generalized gamma, log-logistic and lognormal. The 
aforementioned approaches are explained in chapter 3 and can be integrated into our information 
to ascertain their suitability.  
Different models can be classified as: proportional hazards model (exponential and Weibull) and 
proportional odds model (log-logistic). Figure 1.2 illustrates that the Weibull and exponential models 
can be both the accelerated failure time (AFT) model and proportional hazards model. In addition, it 
provides the commonly used parametric models. 
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Table 1.2: The main models for survival analysis  
Technique Goal 
Kaplan-Meier Estimate the probability of an individual 
surviving for a given time period 
Log-rank Test Compare survival of two different groups 
of individuals. 
Cox regression Detect clinical/ genomic/ epidemiologic 
variables, which contribute to the risk. 
Accelerated failure time (AFT) Used as an alternative model to the Cox 
model where the proportional hazard 
assumption is not held constant. 
 
 
Figure 1.2: Parametric models in survival analysis (Sewalem, 2012). 
The above methods have different properties and interpretations. However, each model can 
summarize survival data. 
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The steps of the survival analysis using R programming are shown in Figure 1.3 (Yang et al., 
2011). 
 
Figure 1.3: Steps for analyzing the clinical trial data for survival analysis in R. 
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1.3 Objectives 
There are some essential goals that are presented in the current study in order to clearly 
understand the important meaning of the survival analysis and how it deals with prostate cancer 
data. 
1. The objective of the present study is to address some important questions related to 
prostate cancer survivorship for patients with primary or metastatic tumor. It is commonly 
understood that the risk of developing prostate cancer is higher in metastatic tumor than 
the primary. The objective of this thesis is to examine the efficiency of several methods 
that are commonly used to estimate survival functions in the presence of censored data. 
Kaplan-Meier analysis was performed to estimate survival in univariate analysis. We 
compare different techniques to estimate survival functions. 
2. This research investigates the influence of standard clinical prognostic features on the 
survival time of prostate cancer patients. Particularly it seeks independent variable 
patterns to determine the survival times and identify the correlations among the variables 
of interest. For this goal the Cox model performed well, which identified covariates 
associated with survival. 
The rest of the thesis is organized as follows: 
Chapter 2 provides a literature review on survival analysis for cancer dataset. Chapter 3 presents 
the data set and its description to clearly understand it.  Additionally, it provides in detail the 
methodology that was performed for survival analysis suitable for the given data. Chapter 4 
summarizes and discusses the results. Chapter 5 concludes the study. Finally, appendices 
summarize R code and a few outcomes. 
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Chapter 2 
Literature Review 
2.1 Survival Analysis Study 
Litwin, et al., (2000) faced significant challenges that kept them from bringing data together from 
different studies in order to assess disparities in results of treatment in various institutions. 
Initially, they were presented with different endpoints from the studies. Following this, they 
noticed that the different studies showed varying disease severity. Finally, usefulness of the 
results was limited by the differences in the techniques used to measure patient-focused 
outcomes. There are several clinical trials where survival analysis model was used. We present 
here some of the techniques of survival analysis for cancer data especially prostate and breast. 
 Vinh-Hung, V. et al. (2002), Post-surgery radiation in early breast cancer: survival analysis of 
registry data 
Vinh-Hung et al (2002) showed the survival advantage in patients diagnosed with early breast 
cancer, treated with post-surgery radiation. The current study tries to prolong these results 
through an organized population data analysis. This study made use of Epidemiology, 
Surveillance, and End Results (SEER) data on 83,776 women suffering from breast cancer 
diagnosed between 1988 and 1997, stage T1–T2, node positive or node negative. The 
proportional hazard models were used for the analysis.  
Results showed that the best rates of survival were found with combined radiation and breast-
conserving surgery in all cases. The available data indicate that post-surgery radiation provides a 
survival advantage irrespective of the type of surgery in node positive patients. Likewise, survival 
advantage was observed with post-surgery radiation and breast-conserving procedure in node 
negative patients. 
 
 Ray, M.E. et al. (2009), Potential surrogate endpoints for prostate cancer survival: analysis of 
a phase III randomized trial 
In their study, Ray, M. E. et al. (2009) determined that surrogate endpoints for prostate cancer 
specific survival may reduce the length of the clinical trials for a patient’s prostate cancer. This 
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study assessed distant metastasis and failure of general medical treatment as possible substitutes 
for prostate cancer-specific survival using data from the Radiation Therapy and Oncology Group 
92-02 randomized experiment. 
They use data where patients (n = 1554 assigned randomly and 1521 evaluable for the study) 
having locally advanced prostate cancer had undergone 4 months with neoadjuvant and 
simultaneous androgen deprivation therapy with external treatment of beam radiation. These 
patients were then randomly assigned to either no additional treatment (control arm) or 24 extra 
months of androgen deprivation therapy (experimental arm). Statistics coming from the point of 
origin of examinations at three and five years for failure of general clinical treatment (meaning 
the recorded progression of local disease, distant or regional metastasis, induction of androgen 
deprivation therapy, or a prostate-specific antigen level of 25 ng/mL or more following radiation 
therapy) and/or distant metastasis were examined as substitute final stages for prostate cancer-
specific survival at 10 years using Prentice's four criteria. The Cox proportional hazard (PH) 
models were utilized to provide the hazard ratio (HR) between the treatments. All statistical 
investigations were two-sided. 
At 3 years, 1364 patients were surviving and provided data for evaluation. Both general clinical 
treatment failure and distant metastasis at 3 years indicated consistency with all four of Prentice's 
criteria for being a substitute for final stages for prostate cancer-specific survival at 10 years. At 5 
years, 1178 patients were surviving and offered more data for evaluation. Even if prostate cancer-
specific survival did not statistically vary substantially between arms of treatment at 5 years (P = 
.08), both final stages showed consistency with the remaining Prentice's criteria. They concluded 
that general clinical treatment failure and distant metastasis at 3 years may be possible with 
alternative endpoints for prostate cancer-specific survival at 10 years. However, these final stages 
must be verified with other collections of data. 
Chan, Y.M. (2013), Statistical Analysis and Modeling of Prostate Cancer 
The study performed by Chan (2013) provided a comparison of survival between African 
American and White men at the four distinct stages of prostate cancer under the same treatment.  
Moreover, the study made it possible to estimate the average difference in survival between 
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White and African American males diagnosed with prostate cancer and addressed some of the 
critical issues related to treatment.  
There is a common perception that African American men have a greater risk of developing 
prostate cancer than men of other races. Nevertheless, with the use of parametric analysis, Chan’s 
study showed that the perception is more of a myth than reality. The study further recognized the 
presence of racial/ethnic differences by relating the average size of tumors, the median time of 
survival time, and the survival function between African American and White men. These 
outcomes emphasize the need for acknowledging the role that racial background plays in 
improving clinical targeting, and in so doing, advancing clinical results. Moreover, parametric 
survival analysis was conducted to approximate the survival rate of white men going through 
various treatments at every stage of prostate cancer. In addition, to comprehend the risk factors 
(tumor size, age, age and tumor size interaction) linked with survival time, a framework of 
accelerated failure time was created. The model could precisely forecast the survival rates of 
white men at each stage of prostate cancer according to the received treatment. 
Lastly, the outcomes of parametric survival analysis and the framework of accelerated failure 
time model are compared among white men going through the same treatment at each disease 
stage. 
Pulte, D. (2012), Changes in survival by ethnicity of patients with cancer between 1992–1996 
and 2002–2006: is the discrepancy decreasing? 
The study organized by Pulte et al (2012) emphasized that those patients of marginal race or 
ethnicity report lower rates of survival in most of cancer diagnosis cases. Over time, there exists 
few data regarding changes in the differences. Here, they evaluated changes in survival rates of 
patients with common cancers in two latest periods of time by ethnicity or race. 
In their methods they utilized a structured period analysis to define relative survival (RS) for 
African–American (AA), non-Hispanic white (nHw), and Hispanic patients in the Epidemiology, 
Surveillance, and End Results database detected with usual solid and hematological distortions. 
The results show the RS for five years became better for nHw for every tumor detected, between 
+2% points (pancreatic cancer) to +16.4% points [non-Hodgkin's lymphoma, (NHL)]. Greater 
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progress was seen for Hispanics and AA than nHw in NHL, and prostate and breast cancer. There 
was less improvement for Hispanics and AA than for nHw for pancreatic and lung cancer. 
Statistically, for Hispanics and AA with acute leukemia or myeloma, no substantial improvement 
was observed. Disparities in survival remained between AA and Hispanics from 0.5% points for 
myeloma to 13.1% points for breast cancer  
They conclude that there has been advancement in reducing the differences in survival between 
minorities and nHw in NHL, prostate and breast cancer. Minimal improvement has been possible 
in decreasing the differences for their cancers.   
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Chapter 3 
Materials and Methodology 
3.1 The Data source 
Prostate survival data was obtained and generated from the Memorial Sloan Kettering Cancer 
Center (MSKCC). At MSKCC, each sample had been collected from the recipients of radical 
prostatectomy treatment. Out of the sample group, 181 patients were diagnosed with primary 
tumors along with one patient who has both metastases and primary tumor and 37 with 
metastases including the aforementioned patient. The association between survival, the tumor 
type, and the raw data contains 230 cases (rows) and 164 variables (columns). Additionally, for 
this recent analysis 40 variables have been chosen to improve the results. Detailed description of 
the data set can be found in the article written by Taylor et al. (2010).  The format of the dataset 
is shown in Table 3.1, where they defined the data such as the type of tumor (primary or 
metastatic), age (years), race (White Non-Hispanic, Black Non-Hispanic, White Hispanic, and 
Black Hispanic) and so on. The data was converted from a factor into numeric, in order to apply 
it in R.  
The data collected from MSKCC has some primary criteria to select patients after the radical 
prostatectomy (RP) treatment: 
• Serum PSA testing every 3 months for the first year, 6 months for the second year, 
and annually thereafter. For all analyses described here, biochemical recurrence 
(BCR) was defined as PSA ≥ 0.2 ng/ml on two occasions. 
• Following radical prostatectomy, patients were followed-up with history, and 
physical exam. 
• The size of the primary tumor was known 
• Initial biopsy Gleason score is between 6 to 9. 
• At the time of data analysis, patient follow-up was completed through December 
2008. The age was between 37.3 and 83. 
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Table 3.1: Clinical trial data of prostate cancer. 
Sample ID Type MetSite Race PreDxBxPSA DxAge BxGG1 …. 
PCA0171 PRIMARY NA White Non-Hispanic 8.20 60.87 3.00 …. 
PCA0172 PRIMARY NA White Non-Hispanic 17.20 52.00 4.00 …. 
PCA0173 PRIMARY NA White Non-Hispanic 5.24 66.16 3.00 …. 
PCA0174 PRIMARY NA White Non-Hispanic 4.60 54.32 4.00 …. 
PCA0175 PRIMARY NA Black Non-Hispanic 5.60 51.00 3.00 …. 
PCA0176 PRIMARY NA Black Non-Hispanic 8.10 53.55 3.00 …. 
PCA0177 PRIMARY NA White Non-Hispanic 5.63 59.78 4.00 …. 
PCA0178 PRIMARY NA White Non-Hispanic 4.60 61.83 3.00 …. 
PCA0179 PRIMARY NA White Non-Hispanic 40.24 64.89 4.00 …. 
PCA0180 PRIMARY NA White Non-Hispanic 8.03 67.17 4.00 …. 
PCA0181 PRIMARY NA White Non-Hispanic 27.00 69.01 4.00 …. 
PCA0182 MET Node White Hispanic 30.00 58.00 4.00 …. 
PCA0183 MET Bone White Non-Hispanic 182.10 82.00 5.00 …. 
PCA0184 MET Node White Non-Hispanic 27.00 69.00 3.00 …. 
PCA0185 MET Node White Non-Hispanic 27.00 69.00 3.00 …. 
…. …. …. …. …. …. …. …. 
 
The headings found in Table 3.1 are described in detail using proper medical language in Figure 
3.1.  
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Figure 3.1: Description of the clinical data for prostate cancer. 
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Descriptive statistics can provide some information about the distributions of the variables such 
as the average, minimum and maximum time in days for the censored and failed observations. In 
our data the descriptive statistics provided information for the two types of tumors: primary and 
metastatic as shown in Table 3.2. Patients in our study ranged in age from 37.3 to 83 years.  
An example of these statistics can be found in the following table. As the table shows, the PSA 
value was tested at less than 4, between 4 and 10, and greater than 10 ng/ml. There are 31 
(17.2%) patients with primary tumors whose PSA was less than 4, and 4 patients of metastatic 
(12.5%).   There are 105 (58.3%) patients with primary tumors whose PSA was between 4 and 
10, and 6 (18.75%) patients of metastatic. Finally, there are 44 (24.5%) patients with primary 
tumors whose PSA was greater than 10, and 22 (68.75%) patients with metastatic. 
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Table 3.2: Descriptive statistics for the distributions of the variables (Taylor et al., 2010). 
Characteristic Primary tumor Metastatic 
Age   Median 58.3 60 
Mean 58.3 60 
Standard 
deviation 
7 8.6 
Min-max 37.3–83 41–82 
PSA at diagnosis 
(ng/ml)   
Median 6 (IQR 4.4, 9) 
17 (IQR 8.6, 
46.6) 
<4 31 (17.2%) 4 (12.5%) 
4–10 105 (58.3%) 6 (18.75%) 
>10 44 (24.5%) 22 (68.75%) 
Initial biopsy 
Gleason score   
5 2 (1%) -- 
6 101 (56%) 2 (6%) 
7 61 (34%) 16 (46%) 
8 11 (6%) 8 (23%) 
9 6 (3%) 9 (25%) 
Initial clinical 
stage   
cT1c 95 (52.4%) 8 (22%) 
cT2 76 (42%) 12 (33%) 
cT3 9 (5%) 3 (8%) 
cT4 -- 1 (3%) 
Not available -- 9 (25%) 
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3.2 Methodology 
We examine non-parametric, semi-parametric and parametric methods to estimate the survival 
function for the given data. 
3.2.1 Non-parametric Methods 
Kaplan Meier Estimates (K-M) 
The first point to consider is how censoring can be adjusted in the K-M method in order to 
estimate the survival function. As the K-M method makes no assumption about the shape of the 
underlying survival curve, it is categorized as a non-parametric method for estimating a survival 
function. However, using a non-parametric analysis typically generated much wider confidence 
bounds than those calculated via parametric analysis. Parametric analysis shows how predictions 
outside the range of observations are not possible with non-parametric analysis.  
As we have defined earlier in chapter 1, the survival function is the mathematical equation that 
describes a smooth curve, depicting the lifetime of the population of interest. When the survival 
time differs especially when some subjects are excluded in the study, K-M curve is one of the 
most common curves to tackle the likewise circumstances. 
The characterization of all the subjects of the survival analysis by K-M method can use only three 
variables (Rich, et al., 2010). The first variable is the serial time which begins with the 
commencement of the treatment and gets censored from the study when it reaches the end point. 
At the end of the serial time, the second variable consists of the patient’s status. The third 
variable is the study groups the patients belong to. 
The idea of this method is based on the probability of the surviving in k or more periods in the 
study and is a product of k probabilities when each period is observed under it. It is written by the 
following expression: 
𝑆(𝑘) =  𝑝1  ×  𝑝2  ×  𝑝3  × … × 𝑝𝑘                                     (Bewick, et al., 2004) 
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In the above equation 𝑝1 constitutes surviving proportion in the first period, 𝑝2 is the proportion 
survived over the second period, and so on. The equation below gives the proportion of surviving 
for period 𝑖 where they survived up to period 𝑖: 
 
𝑝𝑖 =  𝑟𝑖 − 𝑑𝑖𝑟𝑖  
Where, 
𝑟𝑖 is the number of patients living at start of the period 𝑖, and   𝑑𝑖 is the number of deaths. 
Considerations in the K-M curves: 
Identifications have to be made in the analysis of the K-M curve regarding the units of 
measurement according to the axes and the events of interest. After that, the evaluation of the 
curve, the number of the censored subjects and their distribution are very important. The number 
of participating subjects is much more if the curve consists of many small steps. However, 
limited number of participating subjects results in a curve with large steps. The time period of 
being alive of those patients who have been treated is measured in many medical studies. 
In current study survival package of R program was used for survival analysis. In our data the 
first variable to characterize each subject of K-M survival analysis is the serial time in the column 
BCR_FreeTime, which is time until death (in months). The second variable status is given by 
column BCR_Event, its event (after RP as defined by rise of PSA level). The time to event 
(death) was estimated for a group of individuals. The third variable study group is the type of 
prostate cancer (primary or met). The instruction in R to estimate the survival function is given 
by: 
pFit <- survfit(Surv(BCR_FreeTime, BCR_Event) ~ Type, data = clinData) 
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The results sorted by ascending serial times beginning with the shortest times for each group are 
shown in Chapter 4. A subset of the data is used to look at primary tumors only according to the 
tumor Gleason score to show the estimate the survival time and to show which tumor grade has a 
higher rate.  
The median is chosen for a summary measure as the distribution of survival time is positively 
skewed. Therefore, the median survival time is defined as 50% of the individuals under study 
expected to survive in their time. 
Log Rank 
The K-M survival curves can provide us an idea about the difference between survival functions 
among two or more groups. However, it cannot give us whether this observed difference is 
statistically significant. Hence, many methods can be utilized to test the equality of the survival 
functions for different groups. The log-rank is one commonly used non-parametric test for 
comparing two or more survival distributions of the patients; it is also called Mantel log-rank. 
Additionally, this method is useful when the risk of an event is always greater for one group than 
another in order to detect a difference between groups.  
The steps to complete this method start with arranging the survival time for both censored and 
observed times. The log rank test is a form of Chi-square test distribution with one degree of 
freedom (Singh, and Mukhopadhyay, 2011) that calculates a test statistic used for testing a null 
hypothesis. In our study the log rank test was used to test the null hypothesis that the survival 
curves for all groups are the same. To clarify, it was used to test whether or not there is a 
difference between the populations in the probability of an event (here death) at any point in time. 
For each point of time the observed number of deaths in each group and the number of expected 
deaths are calculated to determine if there was a difference. The number of expected deaths is 
determined by multiplying the total number of events at a given point in time with the proportion 
of subjects who are at risk at that point (Dakhil, et al., 2012). 
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The calculation of the test is: 
𝑋2(𝑙𝑙𝑙𝑙 𝑟𝑟𝑙𝑘) =  (𝑂1−𝐸1)2
𝐸1
+  (𝑂2−𝐸2)2
𝐸2
                             (Bewick, et al., 2004) 
Here, 𝑂1 and 𝑂2stand for the number of total events that have been observed within the groups of 
1 and 2 respectively. 
The expected number of events is represented by 𝐸1 and𝐸2. 
The survdiff function in R implements the log rank test. In our study, this method is useful to 
detect the difference between two groups of tumor - primary and metastasis. 
logDiff <-  survdiff(Surv(BCR_FreeTime, BCR_Event) ~ Type, data = clinData) 
3.2.2 Semi-parametric Methods 
Cox proportional hazard 
The non-parametric methods are not useful for controlling the covariates and it requires 
categorical predictors. Therefore, the multivariate approaches are used when we have several 
prognostic variables. The most widely applicable and broadly implemented multivariate method 
in the survival analysis is the regression model of the Cox proportional hazards. In the year 1972 
Cox showed the first light to the Cox model (Fox, 2002). The explanatory variables (determining 
the features of the patients with the estimation of the number of covariates and risk of death) and 
the response variables are combined. As any form can be adopted by the disturbance of the 
baseline, the nature of the model is semi-parametric (Fox, 2002). Disturbances are defined as the 
hurdles of death and the moments risked by death, which have been outlasted by the patients 
within a given period of time. There can be a number of homogenous regression models of Cox 
but hazard function is the variable to depend upon. However, the time factor does not affect the 
hazard function as it does in the survival function. 
The Cox model, a regression method for survival data, provides an estimate of the hazard ratio 
which is always non-negative and its confidence interval. The hazard ratio is an estimate of the 
ratio of the hazard rate based on comparison of event rates. The hazard rate is the probability that 
if the event in question has not already occurred, it will occur in the next time interval, divided by 
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the length of that interval. The time interval is made very short, so that in effect the hazard rate 
represents an instantaneous rate. An assumption of proportional hazards regression is that the 
hazard ratio is constant over time. 
The mathematical equation of the Cox model is: 
ℎ(𝑡) = exp{ ℎ0 (𝑡) + 𝑏1 𝑥1 + 𝑏 2𝑥2 + ⋯+  𝑏 𝑝𝑥𝑝} 
Or             logℎ(𝑡) =  ℎ0 (𝑡) +  𝑏1𝑥1 + 𝑏 2𝑥2 + ⋯+  𝑏 𝑝𝑥𝑝     (Fox John, 2002) 
Here, 
h(t) represents the hazard function within the limited time period of t. 
The covariates of x1, x2, …., xp are also the explanatory variables. 
If each explanatory variable xi is zero (exp  ℎ0 (𝑡) =1) then the hazard of the baseline is 
represented by ℎ0(t). If covariates (risk factors) is characterized by dichotomy and is coded 1 if 
present and 0 if absent, respectively. 
According to the implication of the proportionality, the quantities exp(bi) are known as the ratios 
of hazards. The interpretation of the quantity exp(bi) is  an event when relative risks are evolved 
immediately irrespective of time . The individuals with the risk factors and individuals without 
the risk factors work equally with all the covariates. If the covariates are presupposed to be 
continuous then the interpretation of the quantity exp(bi) is an event where the risk factors are 
evolved immediately irrespective of time where the value of the covariate increased by 1 was 
compared  with another individual provided the effects of all the individuals on the covariates are 
same. Binary and continuous are the two types of covariates. The h (t)/ ℎ0 (𝑡) is known the 
hazard ratio.  
The statistic package that triggers the changes in the hazards that are anticipated, helps to 
estimate the coefficients 𝑏1, 𝑏 2… 𝑏 𝑝. Since this method focuses on the relation, it is necessary 
for us to interpret the coefficients for each explanatory variable. The hazards will increase if the 
occurrence of the regression coefficient in explanatory variables is positive, and the hazards 
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decrease as an improved prognostic is yielded by the regression coefficient only when it is 
negative. 
A Cox model was fitted by using an appropriate computer program in R to find the equation for 
the hazard as a function of several explanatory variables. This model was used to investigate the 
influence of standard clinical prognostic features on the survival time of Prostate cancer patients: 
Before we fit the Cox proportional hazard, the variables should be converted to numeric as 
follows: 
clinData $PathStage <- as.numeric(clinData $PathStage) 
clinData $PathGGS <- as.numeric(clinData $ PathGGS) 
clinData $ PathGG2 <- as.numeric(clinData $ PathGG2)  
 
The best fit model with four explanatory variables is given by: 
coxFit2 <- coxph(formula = Surv(BCR_FreeTime, BCR_Event) ~ PreDxBxPSA + PathGGS + 
PathGG2 + PathStage, data = clinData) 
The Adequacy of a model:  
When clinical trials are performed, the primary analysis of the biomedical and biological 
applications has a number of available variables. However, the number of predictable errors can 
increase if the covariates are invalid (Liang and Guohua, 2008). The task of determining 
covariates for the statistical model has always been very sensitively critical in the process of data 
analysis. The selection of a proper model is broadly depended on the Akaike’s information 
criterion (AIC). 
AIC is applied in order to choose one model from two competing ones having the possibilities of 
various ranges of parameters. The models mostly carry a great number of covariates that are 
feasible and due to this each parameter should be evaluated separately with dynamic scale in 
search of the most befitted model. AIC of lower amount in a model is the finest trigger in the 
betterment of a model (Symonds, et al., 2011).  
The implementation of the proposed method is quite feasible in the concurrent software named 
R/Splus and others. The command used in R for this method is extractAIC.  
coxAIC <- extractAIC(coxFit2) 
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The AIC will be: 
𝐴𝐴𝐴 =  −2𝐿𝐿 + 2(𝑐 + 𝑟)                               (Bradburn, et al., 2003) 
Here, 
The logarithm of the similarities of the models is specified in LL. 
c and a stand for the number of covariates and ancillary parameters respectively. 
Selection of covariates by step-wise selection using p-values: 
For the creation of a preliminary model this is the best-suited approach and it is subject to change 
if its ability of befitting is good. To perform step wise p-value is measured to keep the variable or 
remove the variable from the model. The variable can be kept in the model when its associated 
significance level is less than this p-value. In contrast, if its associated significance level is 
greater than this p-value then the variable will be remove from the model.  
Testing the proportional hazards assumption 
The assumption of proportional hazards (PH) function is the finest techniques in the Cox model. 
This model help clarify the idea that multiplicative effect of each covariate in the hazards 
function is constant over time (Xue, et al., 2013). Quite often the assumption of PH is 
substantially important. The standard cohort studies offer a number of ways by which the 
assessment of the assumption of PH can be approached in addition to the statistical tests and 
graphical methods. “Conversely, graphical methods involve a moderate degree of subjectivity in 
interpretation. Statistical tests typically screen for the lack of fit of a Cox model.” ( Xue, et al., 
2013). 
Using Schoenfeld’s residuals 
To monitor the capability of befitting of a statistical model is best judged by this useful method 
of residuals. The method to be presented here is the scaled residual method. The testing of time 
dependent covariates is the same as the test for a non-zero slope (both are equivalent) on the 
functioning time of the scaled Schoenfeld residuals in a linear regression. If the assumption of 
proportional hazard is violated then it is indicated by a non-zero slope.  
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In a Cox model each predictor variable defines the Schoenfeld residuals. Therefore, both the 
number of predictor variables and Schoenfeld residual variables are same. They are constructed 
on the assistance of each of the predictor variable to the log partial likelihood. The diagnosis of 
Cox regression models is greatly benefitted from the scaled Schoenfeld residuals, particularly in 
the assessment of the assumption of the proportional hazards (Grambsch and Therneau, 1994). 
Theoretically, the adjustments in the Schoenfeld residuals are incorporated according to the 
inverse of the covariance matrix of the Schoenfeld residuals.  By using the slope of scaled 
Schoenfeld residuals against a function of time as our basis for the null hypothesis of the test on 
proportional hazards, it can apply the results to the generalized linear regression approach 
(Grambsch and Therneau, 1994). 
The basis of the null hypothesis of the experiments in the proportional hazards is the scaled 
Schoenfeld residuals, which is the slope of the Schoenfeld residuals. This can be against a 
function of time which is zero for each predictor variables.  
According to Schoenfeld the ith residual value can be plotted against 𝑡𝑖 to verify the assumption 
that residuals are not affected by time. Partial residual is defined as the difference between the 
observed and expected value of 𝑋𝑖  in the risk set 𝑅𝑖 . More precisely, the test statistic for an 
individual predictor variable is: 
𝑟𝑖𝑘 = 𝑋𝑖𝑘 − 𝐸(𝑋𝑖𝑘|𝑅𝑖),                                 (Fitrianto and Jiin, 2013) 
In R program, the function of cox:zph calculates  the assumption of the proportional-hazards with 
respect to covariates as it correlates the transforming time with the respective set of scaled 
Schoenfeld residuals. As a consequence, the proportional hazard assumption (PHA) does not 
need to be rejected provided the larger of p- value (>0.05) and its smaller p-value (<0.05) leads to 
the rejection of PHA. 
In R the command is given as follows: 
Resplot <- cox.zph(coxFit2) 
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Cox- Snell 
Cox- Snell residuals are used as their optimum distribution is achieved in the exponential form. 
As a result when different models with varied distribution are being worked upon, a common 
method can be applied to all of them. The possible drawback of this method lies in the 
nonparametric estimation of the baseline hazard function, which might violate the approximation 
exponentially of the Cox- Snell residuals. 
It must be noted that use of Cox-Snell residuals for assessing the accuracy of survival models has 
not gained wide acceptance particularly when semi parametric Cox- models are used. 
The following equation defines the model as: 
𝑟𝑖 = 𝐻0��𝑇𝑗� exp(𝛽 �𝑋𝚤̀ ) , 𝑖 = 1, 2, … ,𝑙 
where  
 𝑟𝑖  denotes a censored sample from a unit exponential distribution presuming that the applied Cox 
model will hold true.  
𝐻0�  stands for values that lie near the actual value of H0. 
 𝛽 �̀  denotes values that lie near the actual value of 𝛽.  
Plotting the log cumulative hazard plot of Cox-Snell residual with its best fitted straight line in R: 
Htilde <- cumsum(coxph.res2$n.event / coxph.res2$n.risk) 
plot((coxph.res2$time), (Htilde), type = 's', col = 'blue') 
abline(0, 1, col = 'red', lty = 2) 
Martingale residual 
This residual is mainly used to assess how well a Cox model fits a series of observations. The 
martingale residual can actually quantify and produce a variable that will denote the 
interrelationship between a continuous predictor and the survival expectation for individuals.  
This model is examined as the best functional form for the given covariates. 
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The graph can be interpreted easily by superimposing a smoothed curve. There are many of 
smoother curves that can fit to scatterplot. One of the common algorithm used is LOESS or 
LOWESS smooth which is implemented in R package. To calculate the correct functional form 
of the variable, a Cox model is chosen with excluding the variable and a graph is plotted between 
the LOESS smooth of the martingale residuals against some change in the parameters of the 
variable. If the change in the parameters is correct then the graph will show a linear distribution. 
The equation depicting this is given below: 
𝑀𝚤�(𝑡) = 𝑁𝑖 (𝑡) −  � 𝑌𝑖𝑑
0
(𝑠)𝑒?̀?�  𝑋𝚤 (𝑠)̀ 𝑑𝐻0�(𝑠) 
Where: 
 𝑀𝚤�is an acronym for 𝑀𝚤�(∞). The residual is defined at each t, as the  
𝑁𝑖 (𝑡) stands for the number of observed events over a time period t and includes the 𝑖𝑡ℎ subject. 
𝑌𝑖 is a 0-1 process determining if the  𝑖𝑡ℎ subject is a risk at time t. 
𝛽 �̀  which estimate by maximum partial likelihood estimator 𝛽 
𝑒?̀?
�  𝑋𝚤 ̀ is expected value for events for each 𝑖𝑡ℎ subject 
𝐻0�  denotes cumulative baseline hazard.  
At times it is difficult to understand the graphs of martingale residuals as they have a skewed 
distribution and can have values ranging from (-∞, 1). This is the reason why deviance residuals 
are considered a better option for assessing model accuracy and pinpointing outliers. 
The plot of martingale residual can be done for each variable in R as follows: 
plot(clinData2$PreDxBxPSA, rr,xlab="PreDxBxPSA",ylab="Residual") 
lines(lowess(clinData2$PreDxBxPSA, rr,iter=0),lty=2) 
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Deviance residual 
It has been used to work on improperly projected observations. It was introduced by Therneau et 
al (1990) as a solution to the disadvantages of the martingale residual. 
The deviance residual has a more symmetrical distribution about zero and can be defined as: 
𝑑𝑖 = 𝑠𝑖𝑙𝑙(𝑀𝑖)[−2{𝑀𝑖 + 𝛿𝑖  log(𝛿𝑖 −𝑀𝑖)}]12 (Fitrianto and Jiin, 2013) 
Where: 
 𝑀𝑖 denotes martingale residual, function sign (.) stands for the sign function.  
𝛿𝑖 observed number of events for 𝑖𝑡ℎ observation with 1 or 0. 
Observations that lie on the extremes of the deviance residual are those that are not in accordance 
with the model parameters and are designated as outliers. In case of minimum censoring 
approximately < 25% deviance residuals achieve a more symmetrical form as compared to 
martingale residual and the overall distribution is in a pattern that closely resembles normal 
distribution. 
This is how we can get deviance residuals from R: 
plot(coxFit2$linear.predictor, dev.res, xlab = 'Risk Score', ylab = 'Deviance residuals') 
abline(0,0,lty=2,col='red') 
3.2.3 Parametric Methods 
Accelerated Failure Time Model (AFT): 
The type of this model is completely different and the survival time data is evaluated by it. It has 
been presupposed that the linear function of the covariates serves as the time logarithm. It has 
been assumed further that the scale of time would affect the change in the survival of the 
covariates. It has been represented as: log(𝑇𝑖) = 𝑏0 + 𝑏1𝑥1 + 𝑏 2𝑥2 + ⋯+  𝑏 𝑝𝑥𝑝 +  𝜎𝜀𝑖 
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Here, 
𝑏0 refers to the intercept and the unknown coefficients for the values of explanatory variables of p 
are  𝑏0, 𝑏1, 𝑏 2… 𝑏 𝑝. 
𝜎 refers to the scale parameter and the deviation of values of log(𝑇𝑖) is modeled implying a 
random variable-  the quantity 𝜀𝑖. 
In the AFT structure, the survival times are normally supposed to maintain a particular pattern of 
distribution. For presenting survival data of this form, distributions like, log-logistic, log-normal, 
and Weibull can be applied. The AFT supposition is considered in case of comparison between 
survival times. On the other hand, PH supposition is used in case of hazard comparisons. 
According to the AFT process, the impact of the covariates is assumed to work on the log time 
scale and therefore multiplicatively on the time scale itself (Ponnuraja and Venkatesan, 2010). To 
make it simple and easy to express, the time ratio or TR, which is actually the exponentiated 
regression coefficients (i exp (β)), is suggested to express in the same way hazard ratio (HR) is 
interpreted in the models of proportional hazards. When TR is greater than 1 in case of a 
particular co-variant, it infers slowing down or extends the time for the event; on the other hand, 
when TR is less than 1 in case of a particular covariant it depicts higher probability of 
manifestation of the previous event (Khanal, et al., 2012). In order to offer an in-depth 
elucidation citing practical examples using the AFT model, AIC, the process of evaluating the 
rightness of fit of the AFT model is calculated in the following way. The detection plot of the 
Cox-Snell residuals is employed for evaluation of the overall fit of the AFT model.  
Exponential AFT Model: 
In survival studies, exponential distribution is considered as the most simple and the most vital 
form of distribution. Just in the way, normal distribution plays a vital role in different statistical 
cases, in lifetime studies, exponential distribution takes a major role (Hashemian, 2013).  The 
exponential model can be a special case of Weibull model when 1
𝜎
= 1 and 𝜆 is a scale parameter. 
The following equation gives the survival function of exponential distribution: 
𝑆𝑖(𝑡) = exp(−𝜆𝑖𝑡), 
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Weibull AFT Model:  
Weibull Distribution is nothing more than a generalized form of exponential distribution, which 
is extensively used in meteorology for weather prediction modeling and also in radar modeling 
for predicting the distribution of wind. Weibull Distribution is the only type of distribution that 
can be presented as accelerated failure time model as well as proportional hazard model. For the 
purpose of studying survival data, the Weibull distribution is actually borrowed from the field of 
engineering. At the time of study of the applicability of the distribution in the medical science, it 
was noted that the distribution model was vital because there is the probability of uniform 
increase or decrease in the patient mortality rate. Weibull distribution of a survival time T, means 
the same as of the Gumbell distribution of the survival time; and hence the AFT presentation of 
the survival function of Weibull model is represented as:  
𝑆𝑖(𝑡) = exp �−𝜆𝑖𝑡1𝜎�, 
Where, 𝜆𝑖 = exp �−𝜇−?́?𝑖 𝛽𝜎 �, which is a Weibull distribution with shape parameter 𝜆𝑖 and scale 
parameter 1
𝜎
.  
 
The Weibull AFT model is implemented by the “survreg” function from survfit package in R as 
follows: 
weibul12 <- survreg(formula = Surv(BCR_FreeTime, BCR_Event) ~ Type+ Race+ 
PreDxBxPSA+ DxAge+BxGG1+ BxGGS+ ClinT_Stage+ SMS+ ECE+ SVI+ LNI+ PathStage+ 
PathGG1+ PathGGS, data = clinData3, dist="weibull") 
The Cox-Snell residual will take the form  
?̂?𝑐,𝑖 =  exp�𝑙𝑙𝑙(𝑡𝑖) − ?̂? − ?́?𝑖 ?̂?𝜎� � = exp (?̂?𝑐,𝑖) 
In case of a perfect model they will have unit exponential distribution.  
The plot of Cox- Snell was given in R with the command below: 
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plot(cs.fit$time, -log(cs.fit$surv),type = 's',xlab="Cox-Snell residual",ylab="Cumulative hazard 
of residual",main="Cox-snell plot for weibull model") 
Lognormal AFT Model: 
Low value mean, skew distributions, non-negative values and high variance, such as the variety 
of species are usually based on lognormal distribution. It is often applied for retorting to 
intoxicating biological elements, hardware repair time distribution, most patterns of survival data, 
load price study and financial studies. In case the survival times are presumed to be in a 
lognormal distribution, the baseline survival is presented by, 
𝑆𝑖 = 1 −  Φ �log(𝑡) − 𝜇 − ?̀?𝑥𝑖𝜎 �, 
𝜇 𝑟𝑙𝑑 σ are parameters,   
Φ(x) is the cumulative density function of the standard normal distribution. 
The log survival time for 𝑖𝑡ℎ individual has normal (𝜇 + ?̀?𝑥𝑖, σ) 
Logistic AFT Model:  
In case the rate of death for studying the survival reduces gradually after achieving the highest 
within a restricted span, it might be ideal to apply failure rate distribution to find the lifetime. 
Continuous distribution of random variables with probability and non-negative variable is a log-
logistic. This type of distribution is utilized in analysis model of parametric survivals, where at 
the beginning the rate goes radically up and then starts to decrease. 
The survival time even for the 𝑖𝑡ℎ individual can have a log logistic distribution presented as: 
𝑆𝑖 = 11+(𝜆𝑑)𝜎 , 𝜆 >0 
𝜆 is parameterized in term of predictor variables and regression parameters (shape parameter). σ 
is scale parameter. 
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Chapter 4 
Results and Discussion 
In our study, the subject of analysis was the data from 218 patients with prostate cancer that had 
the event (death) after radical prostatectomy (RP), as defined by a rise in PSA level. 
The result of each method was performed by statistical package in R, which was used to analyze 
the data. After applying the Kaplan–Meier (K-M) method to the RP data, the results are tabulated 
in the tables in the following sections. There are some criteria and methods used to validate the 
model and check the over fitting of the model. Finally, the discussion will clarify the meaning of 
the results.   
4.1 Kaplan-Meier (K-M) Estimation 
The construction of a table is a necessary first step in order to analyze the K-M estimate, which 
requires three elements to function. These elements are serial time (survival time by month), 
status at serial time (1= death, 0=censored), and group (1 = primary and 2= Met). An Excel 
spreadsheet was used to build the table, beginning with the shortest times for each group and 
sorted by ascending serial time, which is shown in Table 4.1 below. The initial table is 
preparation for K-M analysis to be used by statistical program R. 
 
 
 
 
 
 
 
 40  
Table 4.1: Initial sorted table for Kaplan- Meier and Log- Rank analysis  
Subject 
Group (1= 
Primary, 2=Met) 
Survival time 
(months) 
Status at serial time (1 
=event, 0 = censored) 
PCA0001 1 18.50 1 
PCA0002 1 58.02 0 
PCA0009 1 64.76 1 
PCA0003 1 93.14 0 
PCA0007 1 98.60 0 
PCA0005 1 126.10 0 
PCA0008 1 149.19 0 
PCA0004 1 152.55 0 
PCA0006 1 160.96 0 
. . . . 
. . . . 
. . . . 
PCA0214 2 0.10 1 
PCA0207 2 1.38 1 
PCA0206 2 1.61 1 
PCA0208 2 11.79 1 
PCA0210 2 20.04 1 
PCA0213 2 64.66 1 
PCA0205 2 NA 0 
PCA0209 2 NA 0 
PCA0211 2 NA 0 
PCA0212 2 NA 0 
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K-M curve 
The plot of survival curves is an important part of survival analysis for each group of interest. 
However, the comparison between two groups is represented by log rank test. In our study, there 
are two types of prostate cancer tumors (Primary, and Met) that were compared to get the 
survival time. From Figure 4.1, the plot of K-M estimate of the survival function plays the role of 
a step function rather a smooth curve, which is between two times (times at adjacent deaths and 
the interval only decrease at each death). In the curve in Figure 4.1 the survival duration for the 
interval is represented by the lengths of the horizontal lines along the X-axis of serial times.  
Moreover, the cumulative probability of surviving a given time is seen on the Y-axis. In addition, 
the vertical distances between horizontals are important because they illustrate the change in 
cumulative probability. When the event of interest occurs, the interval is terminated.  
Some subjects are censored (patients did not die during the follow up) and they are shown as 
vertical bar marks in the graph; these do not terminate the interval. The graph shows the median 
of survival time and the survival rate. 
Presently, we will look at the censored subject as shown in the curve of Figure 4.1. The line of 
the group 1 curve ends with censored subject as seen in the plot. That provides us with a warning 
in terms of interpreting anything beyond this point, because the subjects might have the event 
(death) a few hours later.  In contrast, the line of group 2 has no subjects left and the curve drops 
to zero after the seventeen intervals.  
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Figure 4.1: Survival curve for two tumor groups for the data in Table 4.1. 
 
In Figure 4.2 the fun = “cumhaz” argument in R is used to generate the cumulative hazard curve 
rather than the survival curve for the participant enrolled in the study described above. 
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Figure 4.2: Cumulative hazard curve for the prostate cancer data with two types of tumors. 
Table 4.2 and Table 4.3 can help explain the curve and the way the curve ends. The number of 
patients who are alive in group 1 before the serial time of 1.38 is 180 (column 2). Since one 
patients die at 1.38 (column 3), the probability of dying by a time of 1.38 is 179/180=0.994. The 
number of patients who are alive in group 2 just before the serial time of 0.10 is 17 (column 2). 
Since two patients die in 0.10 (column 3), the probability of dying by 0.10 is 15/17=0.8824. The 
probability for group 1 after 110.33 month is 0.56 (95% CI values from 0.405 - 0.772), while the 
probability for group 2 after the same time is 0. Moreover, the estimate probability for group 2 
after 72 months is 0.0588. 
Table 4.2 and Table 4.3 provide the confidence interval of medians for the survival time. The 
patients with primary tumor have probability of 0.5 to survive longer than 110 months, while the 
patients with metastatic tumor have probability of 0.5 to survive longer than 12 months. Those 
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patients with the primary tumor have a better chance of survival. 
Table 4.2: Calculation for the K-M estimate of the survival function for 
primary tumor. 
Time n.risk n.event Survival std.err 
Lower 95% 
CI  
Upper 
95% CI 
1.38 180 1 0.994 0.00554 0.984 1 
1.41 179 1 0.989 0.00781 0.974 1 
1.64 178 1 0.983 0.00954 0.965 1 
1.81 177 1 0.978 0.01099 0.956 1 
1.87 176 1 0.972 0.01225 0.949 0.997 
2.1 174 1 0.967 0.01339 0.941 0.993 
2.56 173 1 0.961 0.01443 0.933 0.99 
2.92 172 2 0.95 0.01629 0.918 0.982 
3.71 170 1 0.944 0.01712 0.911 0.978 
3.94 169 1 0.939 0.01791 0.904 0.974 
5.72 168 1 0.933 0.01865 0.897 0.97 
6.7 166 1 0.927 0.01937 0.89 0.966 
8.97 163 1 0.922 0.02007 0.883 0.962 
9.86 162 1 0.916 0.02074 0.876 0.958 
10.61 160 1 0.91 0.02138 0.869 0.953 
13.04 156 1 0.905 0.02203 0.862 0.949 
13.21 155 1 0.899 0.02265 0.855 0.944 
16.82 153 1 0.893 0.02325 0.848 0.94 
18 152 1 0.887 0.02382 0.841 0.935 
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18.5 151 1 0.881 0.02438 0.835 0.93 
18.83 150 1 0.875 0.02491 0.828 0.925 
19.02 148 1 0.869 0.02544 0.821 0.921 
20.27 147 1 0.863 0.02594 0.814 0.916 
23.92 143 1 0.857 0.02646 0.807 0.911 
25.13 140 1 0.851 0.02697 0.8 0.906 
27.6 136 1 0.845 0.02748 0.793 0.901 
27.86 134 1 0.839 0.02799 0.786 0.895 
28.65 132 1 0.832 0.02849 0.778 0.89 
30.56 128 1 0.826 0.029 0.771 0.885 
31.21 127 1 0.819 0.02949 0.763 0.879 
31.8 125 1 0.813 0.02998 0.756 0.874 
35.35 121 1 0.806 0.03047 0.748 0.868 
39.49 110 1 0.799 0.03107 0.74 0.862 
39.95 107 1 0.791 0.03166 0.732 0.856 
40.9 106 1 0.784 0.03223 0.723 0.85 
53.82 75 1 0.773 0.03345 0.71 0.842 
55.39 72 1 0.763 0.03467 0.698 0.834 
64.76 48 1 0.747 0.03741 0.677 0.824 
68.04 45 1 0.73 0.04009 0.656 0.813 
80.03 31 1 0.707 0.04519 0.623 0.801 
84.83 24 1 0.677 0.05202 0.582 0.787 
92.98 18 1 0.639 0.06124 0.53 0.772 
110.33 8 1 0.56 0.09199 0.405 0.772 
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Table 4.3: Calculation for the K-M estimate of the survival function for 
Metastatic tumor. 
Time n.risk n.event Survival Std.err 
Lower 95% 
CI  
Upper 
95% CI 
0.1 17 2 0.8824 0.0781 0.74175 1 
1.38 15 1 0.8235 0.0925 0.66087 1 
1.61 14 1 0.7647 0.1029 0.58746 0.995 
2.89 13 1 0.7059 0.1105 0.51936 0.959 
4.11 12 1 0.6471 0.1159 0.45548 0.919 
5.95 11 1 0.5882 0.1194 0.39521 0.876 
11.79 10 1 0.5294 0.1211 0.33818 0.829 
12.68 9 1 0.4706 0.1211 0.28423 0.779 
14.36 8 1 0.4118 0.1194 0.23329 0.727 
18 7 1 0.3529 0.1159 0.18543 0.672 
20.04 6 1 0.2941 0.1105 0.14083 0.614 
41.4 5 1 0.2353 0.1029 0.09987 0.554 
63.9 4 1 0.1765 0.0925 0.0632 0.493 
64.66 3 1 0.1176 0.0781 0.032 0.432 
72.41 2 1 0.0588 0.0571 0.00879 0.394 
110.16 1 1 0 NaN NA NA 
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4.2 Log-Rank Survival Estimates 
Table 4.4: Calculation for the log- rank test to compare tumor groups for the data in Table 4.1. 
Type N O E (O-E)^2/E (O-E)^2/V 
MET 17 17 3.26 57.81 61.5 
PRIMARY 181 44 57.74 3.27 61.5 
The calculation determined that in order to document a significant difference in survival times for 
patients with primary and/or Met tumors, the p-value must be less than 0.05. From the table of 
chi-squared we get the p-value is 4.44e-15 (less than 0.05), then we reject the null hypothesis, 
which is H0: S1(t) =S2(t) because there is difference between the populations in the probability of 
an event (death) at any time point. In Table 4.4, the total number of expected (E) death for group 
1(primary) is calculated as 57.74 and the total number of observed death is 44. In contrast, the 
total number of expected (E) death for group 2 (Met) is calculated as 3.26 and the total number of 
observed (O) death is 17. Therefore, the value of statistic (chi-squared) is calculated as follows: 
61.5. The degrees of freedom are the number of groups minus one, 2 - 1 = 1. Based on our 
calculations, we can conclude that there is significant evidence of a difference in survival times 
for primary and Met. 
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K-M estimation for subset of primary with the Gleason score 
According to the diagnostic factor in prostate cancer we consider the survival time among the 
most affected factors when using the Gleason score with only the group 1 (primary) subset. 
Through our analyses, we want to show if there is a significant difference in survival times within 
primary tumor patients.   
The results show a lot of patients have a Gleason score of 6 and 7, and a lot of the subjects are 
censored as shown in Figure 4.3. Therefore, it gives us a hint that the patients with low Gleason 
score have better survival. In contrast, the grades of 8 and 9 have the highest rate of experiencing 
the event (death), because the Gleason score classified to be a high Gleason score, which 
indicates more aggressive tumors. The table is illustrated in Appendix D which explains the 
curve and how the curve ends for each grade.  
As shown in the figure, there is a big difference between grade 6 and 9. The graph illustrates the 
p- value of 0, which means there is a significant difference for survival times of primary tumor 
patients. This gives us a hint that determining survival time using the Gleason score is dependent 
on the classification within the group.  
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Figure 4.3: Survival times of patients with primary tumor according to Gleason grade.   
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4.3 Cox Fit Model 
As we mentioned before the Cox model yields an equation for the hazard with the explanatory 
variable. The aim from this model is to show the prognostic factor impact on survival. In our 
study, Cox model was applied to our data using PSA levels, tumor stage, secondary Gleason 
grade, and Combined Gleason score as explanatory variables. They are chosen by using the AIC 
and p-value criteria to fit the model. The output is shown in Table 4.5 and Table 4.6. 
The number of value of the cox model was represented as 192 and the number of events was 57. 
There are 26 observations that were deleted due to missing values. 
Table 4.5: Multivariate analysis of prognostic factors for the prostate cancer patient using the Cox 
PH model. 
charactristic Coef exp(coef) se(coef) z P 
PreDxBxPSA 0.00427 1.004 0.00152 2.81 4.90E-03 
PathGGS 1.57581 4.835 0.28147 5.6 2.20E-08 
PathGG2 -0.87512 0.417 0.31551 -2.77 5.50E-03 
PathStage 0.22182 1.248 0.07861 2.82 4.80E-03 
Table 4.6: The hazard rate 
charactristic 
       
exp(coef) exp(-coef) lower .95  upper .95 
PreDxBxPSA 1.004 0.9957 1.0013 1.0073 
PathGGS 4.835 0.2068 2.7847 8.3937 
PathGG2 0.417 2.3992 0.2246 0.7736 
PathStage 1.248 0.8011 1.0701 1.4563 
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Concordance   = 0.838  (se = 0.041) 
Rsquare     =0.361   (max possible= 0.94) 
Likelihood ratio test               = 86.07   on  4  df,         p=0 
Wald test      = 88.1   on  4  df,    p=0 
Score (logrank) test   = 121.2   on  4  df,   p=0 
In the result, there are two tables: Table 4.5 for the coefficients and Table 4.6 for the hazard rate. 
In Table 4.6 the second column presents the regression coefficient. The sign of the coefficients is 
an important issue to consider since a positive sign means the hazard ratio for this variable is 
higher, while the negative sign will decrease the hazard risk (risk of death). For example in 
PathGG2 the coefficient is negative so the risk of death will decrease. Column three in Table 4.5 
presents the estimate of hazard for instance, exp (-0.87512) = 0. 417, which is a 41% decrease in 
the risk of the death for patient with PathGG2.The estimation of hazard increases by exp (1. 
57581) = 4.835for each grade of PathGGS. The fourth column in Table 4.5 is an approximate test 
of significance for each variable, and is obtained by dividing the regression estimate coefficient 
by its standard error SE(coef).  The column z in Table 4.5 records the ratio of each regression 
coefficient to its standard error; a wald statistic is asymptotically standard normal under the 
hypothesis that the corresponding coefficient is zero. Finally, p-value shows the significance of 
the explanatory variable. The asymptotically equivalent tests of the omnibus null hypothesis that 
all of the coefficients are zero are likelihood ratio, wald score, chi-square statistic at bottom of the 
output. We can conclude that in cox model, if the coefficient is negative the hazard will decrease, 
but if the coefficient is positive the hazard will increase.  
The plot of survival curves based on the cox model and Kaplan-Meier Estimates for the model is 
presented in the Figure 4.4. The estimated distribution of survival times for cox model is 
illustrated below by using survefit function graph (function to calculate survival time).  It is 
illustrated the estimate survival function  
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Figure 4.4: The Cox proportional hazard (PH) with error bars show 95% confidence intervals.  
The important step after fitting the model for Cox is to evaluate the adequacy of the fitted model. 
As we mention in Chapter 3 the model that checks the analysis is based on residuals. In the 
analysis for the cox model four major criteria of residuals have been described, they are the Cox-
Snell residual, the deviance residual, martingale residual and the Schoenfeld residual. 
 
 
 
 53  
4.3.1 Testing the proportional hazards assumption using Schoenfeld’s residuals 
The approach of Schoenfeld is the global goodness of the fit test for Cox PH models, which are 
used to detect the insufficiency of covariates in describing the relative risks and the assumption of 
PH.  
From function cox.zph in R (function will test proportionality of all the predictors) we got three 
columns of computation a test for each covariate as shown in Table 4.7. The column rho indicates 
the Pearson product-moment correlation between the scaled Schoenfeld’s residuals and lagged 
residuals for each covariate; the column chisq gives the test statistics and the last row GLOBAL 
gives the global test of proportionality for all the interactions at once as illustrated in Table 4.7. 
The column p gives the p-values. According to these p-values, there is strong evidence of 
proportionality as shown by small global test statistics (large p-value). We compare the result of 
proportional hazards assumption checking by using the graphical and numerical methods.  
The Schoenfeld residuals are computed and plotted against the time for each covariate 
“PreDxBxPSA”, “PathGGS”, “PathGG2’, and “PathStage”. The list of the residuals is ordered 
the same as predictor in the cox model.  
Table 4.7: Scaled Schoenfeld Residuals of Significant Covariates on the PH. 
 
Rho Chisq P 
PreDxBxPSA 0.06080 0.230375 0.631 
PathGGS -0.00391 0.000644 0.980 
PathGG2 -0.07240 0.243562 0.622 
PathStage -0.05141 0.103435 0.748 
GLOBAL NA 1.750937 0.781 
 
As illustrated from the output, it appears that PreDxBxPSA, PathGGS, PathGG2, and PathStage 
satisfy the PHA. According to Table 4.7, they have a slope which is not significantly different 
from zero since the p-values are > α =0.10 in which we failed to reject the null hypotheses. It 
means there is no correlation between each covariates of Cox model and time (not time 
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dependent), which implies that the proportional hazards assumption is fulfilled. Four Smoothed 
scaled Schoenfeld residual plots for these predictors provide an interpretation of the 
proportionality of the model in Figure 4.5. 
 
 
 
 
 
  
 55  
Figure 4.5: Schoenfeld residuals for each explanatory variable versus transformed time in a 
model fit to the prostate cancer data. 
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4.3.2 Evaluating overall model fitting 
Cox-Snell residual is helpful to evaluate the overall model fitting. When the model does not fit 
the data well, cox-Snell does not show any indication of the reason. It only shows whether the 
model is fitted or not. When the step function coincides with the straight line, we say the model 
fits well. 
 
Figure 4.6: Cumulative hazard plot of the Cox-Snell residual for Cox PH model to indicate the 
overall model. 
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4.3.3 Functional Form of Predictors 
Here we investigate the functional form of the covariates. Martingale residual and covariates 
were plotted to observe the covariates functional form. When the functional form is linear or near 
to linear then it would be satisfactory. If the functional form is different from linear, then we have 
to apply some transformation (eg. log, square, square root etc.) of the covariates. 
According to Figure 4.7 below, the martingale residual illustrates a functional form for the 
covariates "PathStage", "PathGGS" and "PathGG2" that seems close to linear. For 
"PreDxBxPSA" the functional form seems not linear. Therefore, we have to apply transformation 
for "PreDxBxPSA". From this functional form of "PreDxBxPSA", log transformation would be 
more logical to use. 
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Figure 4.7: Plot of martingale residuals and lowess smoothed vs. covariates. 
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4.3.4 Checking for Outliers 
We have defined before two types of residuals, which are cox-snell and martingale and it helps to 
obtain the deviance residual. 
Deviance residual was used to detect poorly predicted observations, so we can find outliers. The 
residual deviance shows how well the response is predicted by the model when the predictors are 
included. Figure 4.8 shows that the pattern plot of deviance residual against the risk score seems 
to be symmetrically distributed about zero. This plot is a powerful diagnostic to detect 
individuals whose survival times are out of line. 
 Table 4.8 is illustrated that deviance residuals can be used to identify outliers. 
Table 4.8: Deviance residuals against the risk score 
dev dev.res BCR_FreeTime 
BCR_E
vent 
PreDxBx
PSA 
PathG
GS 
PathGG
2 PathStage 
2 2.643373 0.1 1 17 3 4 5 
6 2.120942 14.357596 1 12.6 2 4 2 
76 2.301396 3.942589 1 14.9 2 4 3 
89 2.252719 23.91838 1 7 1 3 2 
159 2.085014 1.412761 1 4 3 4 5 
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Figure 4.8: Deviance residuals consist of information about the influential and outlier data.  
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4.4 Output of Accelerated Failure Time (AFT) 
These data sets were analyzed using the different AFTs such as exponential, Weibull, log-normal and 
log-logistic models. 
The results from different AFT models applied to prostate cancer progression are presented in 
Table 4.9.There is no significant difference for the estimations in different models. 
Table 4.9: The log-likelihoods and Akaike Information Criterion (AIC) in the AFT models. 
Distribution Loglikelihood K C AIC 
Exponential -256.5 14 1 589.0159 
Weibull -253.5 14 2 585.0454 
LogNormal -256.3 14 2 590.5098 
LogLogistic -254 14 2 586.0415 
AFT models were compared by using statistical criteria (Maximum likelihood (ML) test and 
AIC). According to these criteria, with the AIC (the smaller AIC is better) and higher log-
likelihood value. The computed value of AIC for Weibull AFT model is 585.0454. It appears to 
be an appropriate AFT model compared to the other AFT models as shown in Table 4.10. AIC’s 
are only directly comparable if the number of parameters are the same. AFT model as there are 
two parameters involved.  The AIC for exponential, if it had more parameters, it could be higher 
than 589.0159.    
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Table 4.10:  Results from AFT models for time to progression with Weibull distribution. 
 
Value TR      Std. Error z p 
(Intercept) 6.19138 
 
2.71474 2.2807 2.26E-02 
Type 0.6827 1.979214 0.45513 1.5 1.34E-01 
Race 0.09762 1.102544 0.11617 0.8404 4.01E-01 
PreDxBxPSA -0.00442 0.9955898 0.00179 -2.4685 1.36E-02 
DxAge -0.00189 0.99881118 0.02307 -0.0818 9.35E-01 
BxGG1 -0.33915 0.7123756 0.3929 -0.8632 3.88E-01 
BxGGS 0.24948 1.283358 0.26477 0.9423 2.28E-01 
ClinT_Stage 0.08895 1.093026 0.07374 1.2062 2.28E-01 
SMS 0.31704 1.373057 0.35166 0.9015 3.67E-01 
ECE 0.005 1.005013 0.17329 0.0289 9.77E-01 
SVI -0.18032 0.835003 0.47891 -0.3765 7.07E-01 
LNI 0.81869 2.267527 0.37071 2.2085 2.72E-02 
PathStage -0.23156 0.7932951 0.1316 -1.7595 7.85E-02 
PathGG1 -0.69585 0.4986504 0.35703 -1.949 5.13E-02 
PathGGS -0.91593 0.4001443 0.22176 -4.1302 3.62E-05 
Log(scale) 0.03463 1.035237 0.11168 0.3101 7.56E-01 
Scale= 1.04 
Weibull distribution 
Loglik(model)= -253.5 
Loglik(intercept only)= -331.7 
Chisq= 103.27 on 14 degrees of freedom, p= 1.1e-15 
Number of Newton-Raphson Iterations: 7, n= 190 
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After selecting the best-fitted parametric model from the AFT family, the performance of the 
parametric model was compared with the Cox model based on the Cox-Snell residual method. 
Furthermore, we check the goodness of fit of the model using residual plots. The cumulative 
hazard plot of the Cox-Snell residuals in Weibull model is presented in Figure 4.9; the plotted 
points lie on a line that has a unit slope and zero intercept. 
According to the plot, there is no reason to doubt the suitability of this fitted Weibull model. We 
conclude that the Weibull model is the best fitting the AFT model based on AIC criteria and 
residuals plot. 
 
Figure4.9: Cumulative hazard plot of the Cox-Snell residual for Weibull AFT model 
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We can calculate the acceleration factors and the corresponding confidence interval for every pair 
of groups manually.  
4.5 Discussion 
Several statistical models have been suggested for analyzing special type of data, which is 
referred to as censored data in the survival analysis literature. Non-parametric, semi-parametric, 
and parametric survival models are mainly used in many clinical trials. These models direct the 
form of the conditional hazard function for a given set of variables of the survival time.  
The Kaplan-Meier method gives very good estimations of survival probabilities. The pattern of 
this method in assuming on censoring is independent of the survival time as shown in Figure 4.2. 
Each group of tumors has a pattern independent of the survival time (Langova, 2008). The 
present study has demonstrated that the patients with a primary tumor have a lesser risk than 
those with metastatic considering the latter have the spread of cancer cells in the body. Therefore, 
their survival time will be decreased. The results have provided curve of K-M and the table of the 
survival time which may be useful in comparing the survival time of each group and checking the 
censored data. The survival time for almost 10 years is 0 for metastatic tumors while the survival 
time for those with primary tumors is 0.56 which is evidence of survival. The K-M graph 
displays the cumulative survival function on a linear scale by tumor (Figure 4.1). The survival 
curve of primary tumor patients was lower than that of metastatic tumor patients, which means 
that primary have a higher probability of surviving (not experiencing an event).  
Table 4.3 presented the calculations from the log-rank test to show that there is a significant 
evidence of difference in survival times for groups (primary, and metastatic) since the p-value is 
less than 0.05.  That means there is no significant relation between the survival times of each 
group of tumors. 
The most popular method of examining the effect of explanatory variables on survival is the Cox 
PH model. This model requires the assumption of proportional hazards between strata formed by 
the combinations of levels of the different explanatory variables (Mostafa, 2013). Hence, we 
found the model that only includes the four significant variables, which was chosen with p-value 
and AIC criteria. Additionally, we can conclude that the Cox model was performed to evaluate 
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the joint prognostic significance factors. First, we can say the factor and percentage changes in 
the hazard ratio can be calculated for every significant factor: PathStage, PreDxBxPSA, 
PathGGS, and PathGG2. These variables are the prognostic factors of prostate cancer after 
surgical radical prostatectomy, which predict the hazard rate and show the effectiveness in the 
progress of the disease. Among these prognostic factors are PSA level, secondary grade, Gleason 
scores, and tumor stage. Moreover, these factors could be used to help determine the treatment 
strategy.  
The results in Table 4.5 showed that “Gleason score: PathGGS” has the highly significant (p-
value = 2.20E-08) progression-associated prognosticator. In addition, it gives the hazard ratio of 
4.835 which means 83%. Gleason score remains the most powerful prognostic factors for 
prostate cancer. We can conclude that the important covariates in our study affect the risk is 
Gleason score as proven through medical research (Buhmeida, et al., 2006). Fijikawa et al. (1997) 
also achieved this result in their study, explaining that the Gleason score was an essential 
prognosis factor. In their study, Epstein et al. (2005) revealed that the best prognostic factor in 
prostate cancer was the Gleason score. Similarly, Yigitbasi et al. (2011) detected that the Gleason 
score was an essential prognostic factor.    
The results of the Gleason score with primary tumors are illustrated in Appendix D. In the group 
with the lowest Gleason score (6), it was significant that the time was 110.3 months and survival 
time 0.652. In the group with the highest Gleason score (9), it was 40.9 months and the survival 
time 0.11, which was also significant. Consequently, the Gleason score at the diagnosis of the 
primary tumor indicated to be an independent prognostic factor. 
“PreDxBxPSA: PSA’s level” research has proved that the PSA level is not a very important 
prognostic factor variable. In our study, it has been found that PSA level had the lowest risk of 
death, since exp(0.00427) = 1.004. PSA can be an important factor in diagnosing, following and 
staging prostate cancer. However, in the literature there are different options to determine the 
PSA as evaluating it as prognostic factor (Yigitbasi et al., 2011). Schubert et al. (1994) mention 
that PSA can be helpful for monitoring a patient’s response when the patients have been given 
the treatment. Additionally, it is also useful for the follow-up stage after surgical process relapse 
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and residual tumor. According to Zagars et al. (1995), the PSA is a separate prognostic factor 
regardless of stage and grade. 
For the categorical variable “PathStage: Tumor size stage based on pathologic examination of the 
radical prostatectomy”, it had an affect on the hazard rate by 1.248, which meant a 24% increase 
in the hazard rate. While the last variable” PathGG2: Secondary Gleason grade in the radical 
prostatectomy specimen” decreases the hazard rate with 41%, because it is not one of prognostic 
factors.  
After we chose the best model for Cox, the assumption of PHs were checked with different 
criteria of residuals. These criteria illustrated the usefulness of goodness-of-fit test and offered a 
number of established approaches in determining the validity of a fitted Cox PH model. They are 
the Cox-Snell residual, the deviance residual, martingale residual and the Schoenfeld residual. 
The scaled Schoenfeld residuals were used to check the PH assumption. Martingale residuals and 
deviance residuals were considered for influential observations in models and checking outliers. 
Afterwards the AIC criterion was applied to determine the best model of AFT with four 
distributions. After consideration, the Weibull was determined to be the most appropriate model.  
Table 4.10 presents the Weibull for AFT model and has in column 3 the TR, which is important 
to interpret the results as HR reported in proportional hazards models. As we discussed in chapter 
3, TR> 1 for the covariates reveals that this slows down the time to the event such as Type, Race, 
and BxGGS, while the TR<1 indicates that an earlier event is more likely such as PreDxBxPSA, 
and PathStage.    
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Chapter 5 
Conclusion 
The literature of survival analysis includes postulations of bunch of statistical models in order to 
analyze the censored data in presence of covariates. Different types of models like K-M, Cox PH 
model, and AFT model which are categorized under Non-parametric, semi-parametric, or 
parametric survival models respectively are generally used for agricultural, clinical, or 
biomedical purposes. A study on survival analysis has been done on the prostate cancer patients 
and presented in this thesis. The data for our analysis was taken from Memorial Sloan Kettering 
Cancer Center (MSKCC), especially taking the samples from the patients under the treatment of 
radical prostatectomy. 
Purpose of this study is to find and approximate the survival function and median time of the 
primary as well as metastatic tumors of the prostate cancer. For achieving this goal, K-M method 
has been applied. In comparison with the growth of primary tumors, metastatic tumors are found 
to grow with double chances of spreading the cancer. In order to differentiate the survival curves, 
and log- rank test was applied. Results show the difference in survival rates between the patients 
having either group of tumor growth and these different survival rates were found as significant 
with the p-value of 4.44e-15. 
Depending upon the diagnostic factors of prostate cancer, we are supposed to consider the life 
span among Gleason score along with the primary subset group 1. Additionally, we have shown 
that significant difference exists between the survival times of the patients diagnosed with 
primary tumor growth and having Gleason score. A large numbers of patients have a Gleason 
score 7, and lots of subjects are in censored condition. We conclude that they have lesser risk 
because the survival rate is better than other grade. Those who are identified with score 8 and 9 as 
well, are prone to have higher risk of developing the tumor in comparison with the others. 
According to the results, significant survival difference has been found for the patients identified 
with primary tumors and Gleason score between 6 and 9 and the p value is 0. 
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Function of conditional hazard of the survival time for a certain source of covariates is indicated 
by the Cox PH models. After justifying the explanatory variables, survival curves could be 
determined. Several literatures have been investigated for the prognostic factors, which is used to 
determine the treatment. Additionally, the influences of the standard clinical and pathological 
prognostic factors over the incidence of hazardous prostate cancer patients have been illustrated 
through the results. PSA levels, secondary Gleason grade, Gleason score, tumor stage are the 
considered factors in this case. The Gleason score is identified with higher significant 
progression-related prognosticators revealing the effective mean towards the cases of demise in 
the prostate cancer [HR 4.835, 95% CI 2.7847- 8.3937, p=2.20E-08]. In order to judge the 
goodness of the fit among all of the models of candidate, some specific features of residuals were 
applied.  
AFT model may have a chance of providing a substitute method for fitting few survival data. The 
effective factor to the clinicians is time ratio because it is quite easier for them to track, interpret, 
and more importantly this is very significant indeed. In order to fit the data, we applied four 
diverse models to the dataset, such as Weibull AFT model, log-normal AFT model, log-logistic 
AFT model, and exponential AFT model. Among all the models, Weibull AFT model fits better 
and describes the data best. Moreover using the residual plots we also check with the goodness of 
fit. We mainly used Cox-Snell residuals’ cumulative hazard plot in case of the Weibull model. 
Thus we conclude with the fact that the best fitting model is Weibull model from the aspect of 
AIC criteria in addition with residuals plot. 
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Future work 
To improve the Cox PH model and the accelerated failure models, we could increase the number 
of attributed variables that are significant predictors of survival time such as some relevant risk 
factor, family history, smoking status or race of prostate cancer. These would help to understand 
the characteristics of health behaviors associated with survivorship for prostate cancer patients.  
The other future work could include Markov analysis to examine the progression of prostate 
patients who took different treatments.  
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Appendix A 
# The aim of this code is survival analysis  
# The goal of this is to learn to run Survival analysis using high resolution data from prostate 
cancer study (Taylor et al, Cell 2010).  
# The goal is to understand how to apply the clinical data and learn basic R functions for survival 
analysis.  
 
# Change to my documents where the file is stored 
setwd("/Users/emanalhasawi/Documents/survivalAnalysis") 
 
######### Load the package ############# 
# The R function require (survival) accomplishes the same 
library(survival) 
#read the functions descriptions: 
#Read about the syntax of the Kaplan-Meyer estimator function: 
?survfit 
#Read about the syntax of the log-rank test 
?survdiff 
 
######### read the clinical data in############# 
 
clinData<-read.table("TaylorClinicalData_for_CNA_data.txt", header = TRUE, sep = "\t", 
na.strings = "NA", quote = "", comment.char = "") 
 
######### Run Kaplan-Meyer analysis ############# 
 
#fit and plot Kaplan-Meyer curves for Primary vs Mets: 
pFit <- survfit(Surv(BCR_FreeTime, BCR_Event) ~ Type, data = clinData) 
 
plot(pFit, xlab="Follow-Up Time", ylab="Fraction Surviving", 
+ main="Kaplan-Meier Survival Estimates",col = c("green", "purple")) 
> legend("topright", levels(clinData$Type), lty = 1, col = c("green", "purple")) 
> abline(a=.5, b=0) 
pFit <- survfit(Surv(BCR_FreeTime, BCR_Event) ~ Type, data = clinData, type='fleming' 
plot(pFit, fun="cumhaz", xlab="Follow-Up Time", ylab="Cumlative Hazard", 
+ main="Kaplan-Meier Hazard Estimates",col = c("green", "purple")) 
> legend("topright", levels(clinData$Type), lty = 1, col = c("green", "purple")) 
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######### Run Log-rank test ############# 
# Find and plot log- ranks test for the two groups of the tumors 
 
survdiff(Surv(BCR_FreeTime, BCR_Event) ~ Type, data = clinData) 
 
#define a custom function to pull the p-value out of the Log-rank test 
getPval <- function(x) { 
    if( is.matrix(x$obs)) 
        etmp <- apply(x$exp, 1, sum) 
    else 
        etmp <- x$exp 
    df<- (sum(1 * (etmp > 0))) - 1 
    pv <- 1 - pchisq(x$chisq, df) 
    format(pv, digits = 3) 
} 
pValue<-getPval(survdiff(Surv(BCR_FreeTime, BCR_Event) ~ Type, data = clinData)) 
> pValue 
[1] "4.44e-15" 
legend("bottomright", paste("p-value=", pValue), col = "black") 
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######### Subset the data to look at primary tumors only. Plot survival according to the tumour 
grade ############# 
 
# now we want to look at  subset of primary tumor with only Gleason score in order to get the 
survival time and the difference between the groups of them   
#the factor has to be rebuilt since the column still knows about the #"NA" values;  
#Use columns "Type" and "PathGGS" - Pathological Gleason Grade Score.  
subsetData<-subset(clinData, Type=="PRIMARY") 
subsetData$Type<-factor(subsetData$Type) 
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pFit <- survfit(Surv(BCR_FreeTime, BCR_Event) ~ PathGGS, data = subsetData) 
plot(pFit, , xlab= "Follow-Up Time", ylab= "Fraction Surviving", main=" K-M Surival Estimates 
For Primary With Gleason score", col = c("green", "purple", "magenta", "blue", "orange")) 
legend("topright", levels(subsetData$PathGGS), lty = 1, col = c("green", "purple", "magenta", 
"blue", "orange")) 
pValue<-getPval(survdiff(Surv(BCR_FreeTime, BCR_Event) ~ PathGGS, data = subsetData)) 
legend("bottomright", paste("p-value=", pValue), col = "black") 
 
Appendix B 
 
######### Run Cox proportional hazard ############# 
# Before fit the Cox proportional hazard, the variables should convert to numeric: 
clinData $PathStage <- as.numeric(clinData $PathStage) 
clinData $PathGGS <- as.numeric(clinData $ PathGGS) 
clinData $ PathGG2 <- as.numeric(clinData $ PathGG2)  
 
# Calculate AIC value for each model with the add new variable, and the “best” model is the one 
with minimum AIC value 
coxAIC <- extractAIC(coxFit) 
##### Fit Cox proportional hazard and plot curves for the covariates: 
# combines vector by columns 
clinData2<-
cbind(clinData$BCR_FreeTime,clinData$BCR_Event,clinData$PreDxBxPSA,clinData$PathG
GS,clinData$PathGG2,clinData$PathStage) 
# This function creates data frames, which used for storing data table 
clinData2<-data.frame(clinData2 ) 
 
colnames(clinData2)<-c("BCR_FreeTime","BCR_Event" 
,"PreDxBxPSA","PathGGS","PathGG2","PathStage") 
##remove the cases with missing clinical variables 
clinData2<-na.omit(clinData2) 
 
#dim(clinData2) 
 
#head(clinData2) 
# Run coxph to fits a Cox proportional hazards regression model 
coxFit2<-coxph(formula = Surv(BCR_FreeTime, BCR_Event) ~ PreDxBxPSA +  
 
+     PathGGS + PathGG2+PathStage , data = clinData2, ties = 'breslow') 
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plot(survfit(coxFit2, xlab ="Follow-Up Time", ylab="Hazared Ratio", col = c("green", "purple", 
"red"),main= "Cox PH model") , col = c("green", "purple", "red"),main= "Cox PH model") 
 
summary(coxFit2) 
 
 
####Evaluating proportionality assumption using Schoenfeld residuals for lactation against 
transformed time for each covariate in a model fit 
 
resplot<-cox.zph(coxFit2) 
 
resplot 
 
par(mfrow=c(2,2)) 
 
#plot(cox.zph(coxFit2)) 
 
plot(resplot[1]) 
abline(h=0, lty=3) 
plot(resplot[2]) 
abline(h=0, lty=3) 
plot(resplot[3]) 
abline(h=0, lty=3) 
plot(resplot[4]) 
abline(h=0, lty=3) 
 
###Evaluating overall model fitting 
/*plotting the log cumulative hazard plot of Cox-Snell  
residual with it’s best fitted straight line*/  
#The default residuals of coxph in R are the martingale residuals. 
 
cox.snell <- clinData2$BCR_Event - resid(coxFit2,type = "martingale") 
coxph.res2 <- survfit(Surv(cox.snell, clinData2$BCR_Event) ~ 1) 
#summary(coxph.res2) 
 
Htilde <- cumsum(coxph.res2$n.event / coxph.res2$n.risk) 
plot((coxph.res2$time), (Htilde), type = 's', col = 'blue') 
abline(0, 1, col = 'red', lty = 2) 
par(mfrow=c(1,1)) 
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#####Functional Form of Predictors 
 
## This could be used to determine the functional form of a covariate 
 
clinData2$PreDxBxPSA<-as.numeric(clinData2$PreDxBxPSA) 
coxFit3<-coxph(formula = Surv(BCR_FreeTime, BCR_Event) ~1,data=clinData2) 
rr<-resid(coxFit3)  
 
 
 
#martingle residual 
par(mfrow=c(2,2)) 
plot(clinData2$PreDxBxPSA, rr,xlab="PreDxBxPSA",ylab="Residual") 
lines(lowess(clinData2$PreDxBxPSA, rr,iter=0),lty=2) 
plot(clinData2$PathGGS, rr, xlab=" PathGGS",ylab="Residual") 
 
lines(lowess(clinData2$ PathGGS, rr,iter=0),lty=2) 
 
plot(clinData2$PathGG2, rr, xlab="PathGG2",ylab="Residual") 
 
lines(lowess(clinData2$PathGG2, rr,iter=0),lty=2) 
 
plot(clinData2$PathStage, rr, xlab="PathStage",ylab="Residual") 
 
lines(lowess(clinData2$PathStage, rr,iter=0),lty=2) 
 
 
#Checking for Outliers by 'Deviance residual 
 
dev.res <- resid(coxFit2, type = "deviance") 
 
#length(dev.res) 
 
#length(clinData2$BCR_FreeTime) 
 
plot(coxFit2$linear.predictor, dev.res, xlab = 'Risk Score', ylab = 'Deviance residuals') 
 
abline(0,0,lty=2,col='red') 
 
cbind(dev.res, clinData2)[abs(dev.res) > 2, ] 
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Appendix C 
 
######### Run AFT   model with specific distribution ############# 
 
# Apply AFT with four distributions 
clinData<-read.table("TaylorClinicalData_for_CNA_data.txt", header = TRUE, sep = "\t", quote 
= "", comment.char ="") 
 
clinData3<-
cbind(clinData$BCR_FreeTime,clinData$BCR_Event,clinData$Type,clinData$Race,clinData$Pr
eDxBxPSA,clinData$DxAge,clinData$BxGG1,clinData$BxGGS,clinData$ClinT_Stage,clinData
$SMS,clinData$ECE,clinData$SVI,clinData$LNI,clinData$PathStage,clinData$PathGG1,clinDa
ta$PathGGS) 
clinData3<-data.frame(clinData3) 
 
colnames(clinData3)< 
c("BCR_FreeTime","BCR_Event","Type","Race","PreDxBxPSA","DxAge","BxGG1","BxGGS"
,"ClinT_Stage","SMS","ECE", "SVI","LNI","PathStage","PathGG1","PathGGS") 
#str(clinData3) 
##remove the cases with missing clinical variables 
clinData3<-na.omit(clinData3) 
 
exponenl12= survreg(formula = Surv(BCR_FreeTime, BCR_Event) ~ Type+ Race+ 
PreDxBxPSA+ DxAge+BxGG1+ BxGGS+ ClinT_Stage+ SMS+ ECE+ SVI+ LNI+ PathStage+ 
PathGG1+ PathGGS, data = clinData, dist="exponential") 
> aicexpo= extractAIC(exponenl12) 
 
> logaic12= survreg(formula = Surv(BCR_FreeTime, BCR_Event) ~ Type+ Race+ 
PreDxBxPSA+ DxAge+BxGG1+ BxGGS+ ClinT_Stage+ SMS+ ECE+ SVI+ LNI+ PathStage+ 
PathGG1+ PathGGS, data = clinData, dist="loglogistic") 
> aicloglog= extractAIC(logaic12) 
 
> lognorm12= survreg(formula = Surv(BCR_FreeTime, BCR_Event) ~ Type+ Race+ 
PreDxBxPSA+ DxAge+BxGG1+ BxGGS+ ClinT_Stage+ SMS+ ECE+ SVI+ LNI+ PathStage+ 
PathGG1+ PathGGS, data = clinData, dist="lognormal") 
> aiclognorm= extractAIC(lognorm12) 
 
weibul12= survreg(formula = Surv(BCR_FreeTime, BCR_Event) ~ Type+ Race+ 
PreDxBxPSA+ DxAge+BxGG1+ BxGGS+ ClinT_Stage+ SMS+ ECE+ SVI+ LNI+ PathStage+ 
PathGG1+ PathGGS, data = clinData, dist="weibull") 
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 aicweible12= extractAIC(weibul12) 
 
weibul12= survreg(formula = Surv(BCR_FreeTime, BCR_Event) ~ Type+ Race+ 
PreDxBxPSA+ DxAge+BxGG1+ BxGGS+ ClinT_Stage+ SMS+ ECE+ SVI+ LNI+ PathStage+ 
PathGG1+ PathGGS, data = clinData3, dist="weibull") 
summary(weibul12) 
 
hat.sig = weibul12$scale 
hat.alpha = 1/hat.sig 
reg.linear = weibul12$linear.predictor 
reg.linear.mdf = -reg.linear/hat.sig 
tt=cbind(Surv(clinData3$BCR_FreeTime, clinData3$BCR_Event))[,1] 
cs.resid = exp(reg.linear.mdf)*tt^(hat.alpha) 
 
cs.fit = survfit(Surv(cs.resid,clinData3$BCR_Event)~1,type="fleming-harrington") 
#summary(cs.fit) 
par(mfrow=c(1,1)) 
plot(cs.fit$time, -log(cs.fit$surv),type = 's',xlab="Cox-Snell residual",ylab="Cumulative hazard 
of residual",main="Cox-snell plot for weibull model") 
abline(0, 1, col = 'red', lty = 2)   
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Appendix D 
 
PathGGS records n.max n.start Events median 0.95LCL 0.95UCL 
PathGGS=6 53 53 53 4 NA 110.33 NA 
PathGGS=7 102 102 102 21 NA NA NA 
PathGGS=8 12 12 12 8 22.21 8.97 NA 
PathGGS=9 12 12 12 10 5.21 2.56 NA 
PathGGS=Tx 1 1 1 39.49 NA NA 
 
                PathGGS=6  
 
time n.risk n.event survival std.err 0.95LCL 0.95UCL 
23.9 50 1 0.98 0.0198 0.942 1 
40 34 1 0.951 0.0343 0.886 1 
93 7 1 0.815 0.1292 0.598 1 
110.3 5 1 0.652 0.1788 0.381 1 
 
                PathGGS=7  
 
time n.risk n.event survival std.err 0.95LCL 0.95UCL 
2.92 101 1 0.99 0.00985 0.971 1 
3.94 100 1 0.98 0.01386 0.953 1 
5.72 99 1 0.97 0.01689 0.938 1 
9.86 96 1 0.96 0.01951 0.923 0.999 
13.04 92 1 0.95 0.02191 0.908 0.994 
18 91 1 0.939 0.02403 0.893 0.988 
18.5 90 1 0.929 0.02593 0.879 0.981 
18.83 89 1 0.918 0.02766 0.866 0.974 
19.02 87 1 0.908 0.02928 0.852 0.967 
20.27 86 1 0.897 0.03079 0.839 0.96 
25.13 82 1 0.886 0.0323 0.825 0.952 
28.65 76 1 0.875 0.03391 0.811 0.944 
31.21 75 1 0.863 0.03541 0.796 0.953 
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31.8 74 1 0.851 0.0368 0.782 0.927 
35.35 73 1 0.84 0.0381 0.768 0.918 
53.82 47 1 0.822 0.04127 0.745 0.907 
55.39 45 1 0.804 0.04421 0.721 0.895 
64.76 31 1 0.778 0.04981 0.686 0.882 
68.04 28 1 0.75 0.05523 0.649 0.866 
80.03 20 1 0.712 0.06394 0.597 0.849 
84.83 16 1 0.668 0.07384 0.538 0.829 
 
   PathGGS=8  
 
time n.risk n.event survival std.err 0.95LCL 0.95UCL 
1.41 12 1 0.917 0.0798 0.773 1 
1.64 11 1 0.833 0.1076 0.647 1 
2.1 10 1 0.75 0.125 0.541 1 
8.97 9 1 0.667 0.1361 0.447 0.995 
13.21 8 1 0.583 0.1423 0.362 0.941 
16.82 7 1 0.5 0.1443 0.284 0.88 
27.6 6 1 0.417 0.1423 0.213 0.814 
27.86 5 1 0.333 0.1361 0.15 0.742 
 
                PathGGS=9  
  
time n.risk n.event survival std.err 0.95LCL 0.95UCL 
1.38 12 1 0.917 0.0798 0.7729 1 
1.81 11 1 0.833 0.1076 0.647 1 
1.87 10 1 0.75 1250 0.541 1 
2.56 9 1 0.667 0.1361 0.4468 0.995 
2.92 8 1 0.583 0.1423 0.3616 0.941 
3.71 7 1 0.5 0.1443 0.284 0.88 
6.7 6 1 0.417 0.1423 0.2133 0.814 
10.61 5 1 0.333 0.1361 0.1498 0.742 
30.56 3 1 0.222 0.1283 0.0717 0.689 
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40.9 2 1 0.111 0.1014 0.0186 0.665 
 
                PathGGS=Tx_Effects  
time n.risk n.event survival std.err 0.95LCL 0.95UCL 
39.5 1 1 0 NAN NA NA 
 
 
